Prevalence of Streptococcus pneumoniae serotypes causing pneumococcal diseases in the Chinese Mainland: A systematic review and meta-analysis Authors: Jie Che, Bai Peng, Juan Xu, Zhujun Shao Published: 2024 ABSTRACT ABSTRACTPneumococcal disease (PD) caused by Streptococcus pneumoniae (Sp) continues to be a global public health concern. Monitoring the prevalence and shift of Sp serotypes causing PD is critical for vaccination and local policies for PD management. A systematic review of published work on pneumococcal serotype distribution in the Chinese Mainland from January 1997 to July 2023 was conducted. The literature was searched in Medline, Embase, the Cochrane Library, Web of Science, CNKI, and Wanfang. Distribution of the Sp serogroups/serotypes was presented as count and proportion. Pooled distributions were calculated using a double arcsine transformation. Subgroup analyses were performed according to isolate location, strain source, patient age, period, and clinical manifestation. In total 36,477 Sp isolates in 159 studies were included. In the Chinese Mainland, the highest proportion of Sp in PD was serotype 19F, followed by 19A, 23F, 14 and 6B. Serotype 19F was the most predominant circulating serotype through all time periods. PD cases caused by non-vaccine serotypes showed a significant increase after 2019. In summary, from 1997 to 2023, the top 10 prevalent Sp serotypes causing PD in the Chinese Mainland were 19F, 19A, 6, 23F, 14, 6B, 6A, 3, 15B, and 9 V. Although the distribution of serotypes varied according to the subgroups, the increase in non-vaccine serotypes (e.g. 15A), and diversity distribution of serotypes 6A and 3 in different age groups should not be ignored. Introduction Streptococcus pneumoniae (pneumococcus, Sp) is one of the major pathogens of bacterial infectious diseases worldwide. Sp can cause typical infections such as community-acquired respiratory infections, otitis media, sinusitis, and eye infection, as well as life-threatening bacteremia and meningitis.1 PD was divided into invasive PD (IPD), where the strain was isolated from a normally sterile site, and noninvasive PD (NIPD), where the strain was not.2 PD may occur in any age group and is especially frequent among children and the elderly. It was estimated that there were about 829,000 (682,000-1,010,000) pneumococcal-related deaths around the world in 2019, and up to 40.3 million (32.8–50.0) Years of life lost (YLL). Especially among young children post-neonatal to age 4 years 225,000 (180,000-281,000) deaths were associated with Sp.3 Sp is consistently the most prominent cause of lower respiratory tract infections and death.4 The disease burden of PD in adults is mainly determined by community-acquired pneumonia (CAP), for which pneumococcus is the primary pathogen.5 The global incidence has been reported to be between 20 and 1,160 per 100,000 in adults, with higher rates in those older than 65 years.1,5 Given the high burden of PD, the World Health Organization (WHO) considers prevention of PD a high priority.6 Administration of serotype-specific pneumococcal vaccines has proven very effective in preventing PD worldwide.7–9 Since the 1980s, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been recommended for PD prevention.10 The first 7-valent pneumococcal conjugate vaccines (PCV7), licensed in 2000, offered protection against 7 serotypes (4, 6B, 9 V, 14, 18C, 19F, 23F). By 2023, PCV7 was replaced by PCV10 (PCV7 + 1, 3, 7F) and PCV13 (PCV10 + 19A, 6A, 3), which have since been introduced in 162 countries or regions.11 Next-generation vaccines, PCV15 (PCV13 + 22F, 33F) and PCV20 (PCV15 + 8, 10A, 11A, 12F, 15B) were also licensed in 2021 for adults.12 Besides, the Food and Drug Administration (FDA) licensed PCV21 in July 2024 for use in US adults ≥18 years old. However, pneumococci have more than 100 serotypes based on the capsular polysaccharide,8 and the distribution of these serotypes varies both temporally and geographically.9 Furthermore, the use of serotype-specific vaccines has dramatically changed PD serotype epidemiology, causing “serotype replacement.” Despite the continued decrease in vaccine serotypes (VTs) for PD, non-vaccine serotypes (NVTs) have persistently increased, severely compromising the protective efficacy of existing vaccines. Therefore, monitoring serotype distribution and evaluating the dynamic coverage of pneumococcal vaccines is crucial for vaccine choice and local vaccine policy development.10 As a developing country, China has a heavy burden of PD.13 China was estimated to be among the 10 countries with the greatest number of pneumococcal-related deaths in children aged 1 − 59 months in 2000. The global burden of disease working group estimated that China had approximately 7,400 pneumococcal deaths in 2015. It was estimated that there were about 218,200 severe pneumococcal infection cases and around 15,600 deaths in children aged 1–59 months in China in 2017.14 PPSV23 were made available in the private sector in China in 1998 for individuals older than 2 years who had underlying conditions that increased their risk for PD. PCV7 and PCV13 were made available in China in 2008 and 2016. Remarkably, China’s domestically developed PCV13 has remained available since 2021. Several systematic reviews and meta-analyses have been conducted on Sp serotype distribution in the Chinese Mainland.15–17 However, as more cities have included PPSV23 in the Expanded Program on Immunization for older adults18 and the number of children vaccinated has increased,19 the serotype distribution of PD has likely also changed. It is therefore necessary to update data for systematic reviews and meta-analyses, evaluate the coverage of existing pneumococcal vaccines, modify the strategies for pneumococcal vaccination, as well as develop new pneumococcal vaccines. In this study, we collected and systematically reviewed the published literature related to PD for further meta-analysis to illustrate the evolving epidemiology of PD serotypes in China. Objectives The primary objective of this study is to summarize the Sp serotype distribution of PD patients in the Chinese Mainland from 1997 to 2023. The secondary objective is to estimate the Sp serotype distribution in a subgroup of Chinese PD patients according to age, residence, strain source, period, and manifestation. Methods Sources of data and search strategies Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA),20 we identified articles published from January 1997 to July 2023 that reported PD serotype data from four English electronic databases (Medline, Embase, the Cochrane Library, and Web of Science) and two Chinese electronic databases (CNKI and WANFANG). To gather the required data, the following search terms were chosen and combined: “serotype* or serogroup*,” “Chinese or China,” “streptococcus pneumoni* or s* pneumoni* or pneumococc* or diplococcus pneumonia* or diplococcus.” We searched for additional references by cross-checking bibliographies of retrieved studies or relevant reviews. All related studies were reviewed independently by two reviewers (JC and PB). The protocol of this review has been registered in PROSPERO with the approval number of CRD42020205573, and the PRISMA study diagram is shown in Figure 1. Figure 1.PRISMA flow diagram for selection of articles for meta-analysis. PRISMA flow diagram for selection of articles for meta-analysis. Inclusion and exclusion criteria Preliminary screening was conducted by reading the titles and abstracts of the literature. Unqualified studies were removed, and then full-text articles were reviewed in detail against the inclusion and exclusion criteria. Questions concerning the appropriateness for inclusion in the analysis were discussed among the group members and agreed upon prior to proceeding to analysis. We included both experimental and observational studies. Studies were eligible for inclusion with the following items: (1) PD patients; (2) infectious diseases (respiratory tract infection, pneumonia, encephalitis, otitis media, etc.) with Sp positive results; (3) data of IPD that were available but did not indicate if the patients were infected; (4) reported cases were limited to the Chinese Mainland (not including Hong Kong, Macao, and Taiwan); (5) serotypes were reported, and at least one or more of the following indicators were reported: age, period, strain sources, study location, and manifestations. Studies with the following items were excluded: (1) studies that targeted the Sp healthy carriers; (2) non-original research articles, reviews, and any secondary analysis of data, such as meta-analyses or editorial letters; (3) the study data were incomplete and did not include serotype information or were unable to calculate the proportion of serotypes based on the study data; (4) duplicated publications of the same study. Data extraction and data collection Data were extracted using a pretested data collection form. The following data were collected: (1) study characteristics (author, year of publication, city, sample size, study period, serotyping method, and study design); (2) patient characteristics (age group and manifestation); (3) information about Sp isolates (serotype and source); and (4) information on the distribution of Sp serotypes for the subgroups, if any (age, study period, strain sources, study location, and manifestations). For articles that had both invasive and noninvasive Sp strains without indicating the source of the noninvasive strains (noninvasive patient or healthy carrier), only the IPD information was collected. When multiple versions were found for the same population, only the most complete and up-to-date research was included. Data analysis Descriptive analysis, proportions of different serotypes, and changing trends of serotypes of the PD cases were analyzed. All analyses were performed using Stata, version 12.0 (Stata Corp. USA). Pooled event proportions were calculated using a double arcsine transformation to stabilize the variances of the original proportion. Studies with zero proportions were included in the pooled analysis considering their contribution to the whole population. The results of the pooled proportion are presented as the proportion with a 95% confidential interval (95%CI). Heterogeneity was estimated using the Q-test. When the P-value was <0.05 (for Q-test), the result was considered to have heterogeneity and the random-effects model was used for analysis. Otherwise, a fixed-effects model was applied for analysis. Sensitivity analysis was performed to assess the robustness of the results. For individual studies, especially those identified as having a high risk of deviation in the study quality assessment, isolates without detailed serotype information that accounted for >40% were ignored. The magnitude of the impact was calculated. Subgroup analysis was performed on the primary outcome using the following characteristics: 1) strain sources: invasive versus noninvasive stains; 2) clinical manifestations; 3) North-South division: The northern and southern regions of China were divided by the Qinling – Huaihe Line. If a study included patients in both northern and southern regions, it was categorized as a national group and not included in this subgroup analysis; 4) age; and 5) study periods: The study periods were divided into groups to account for every 5 years to identify changes in serotypes. The 5-year period was chosen in order to generate a sufficiently large sample for each period. If a study crossed over two 5-year boundaries, it was assigned to the group that covered a longer time. If the study time was equally divided by the boundary, it was assigned to the latter time group. Results Study characteristics Overall, we identified 4,448 records through database searches and identified an additional 6 articles from the additional sources. Of these, 211 articles were identified for full-text examination after removing duplicates and title and abstract screening. Finally, 159 articles that met our pre-defined eligibility criteria were retained for the final data analysis (Figure 1).21–179 Most of the included studies (125/159, 78.6%) reported information from children (<18 years old). The numbers of studies that reported IPD, NIPD, IPD&NIPD, and unspecified PD were 41, 51, 55, and 12, respectively. All included studies presented test results from isolates, while the test methods varied. In terms of the serotyping test, 104 articles used the Quellung test, 36 used multiple-polymerase chain reaction (MPCR), 18 used both the Quellung test and MPCR, and one study did not specify the serotyping method. The 159 studies included 47 articles with data from North China, 92 articles from South China and 20 studies were national data. The main characteristics of the selected articles are summarized in Table 1.Table 1.Characteristics of 159 included studies.Author, publication yearStudy locationStudy periodTarget populationAgeStrain sourcesTotal tested strainsSerotyping methodNorth China (47 papers)Yv et al. 200021BeijingNov.–Dec.1997Pediatric patients with upper respiratory infection3 months to 5 years oldNon–invasive190Capsule-quellung testLiu et al. 201039Beijing1997–2007Pediatric outpatients with upper respiratory infection<5 years oldNon-invasive893Capsule-quellung testYao et al. 200729Beijing2000–2004pediatric outpatients with upper respiratory infection≤5 years oldNon-invasive129Using 12 pooled antiseraYv et al. 200834Beijing2000–2005Pediatric patients with acute upper respiratory infection<5 years oldNon-invasive519Capsule-quellung testTong et al. 200727Beijing2004Pediatric patients with acute upper respiratory infection≤5 years oldNon-invasive137Capsule-quellung testZhou et al. 201253Beijing2010Pediatric patients with upper respiratory infections<5 years oldNon-invasive135Capsule-quellung testGuo et al. 201684BeijingJan.2010–Dec. 2014Pediatric inpatients with bacteria meningitis<16 years oldNon-invasive12Capsule-quellung testLi et al. 201572BeijingJan. 2012–Mar. 2014Pediatric inpatients with IPDChildrenInvasive21Capsule-quellung test + Using 12 pooled antiseraZhu et al. 2017101BeijingFeb. 2012–Jul. 2014Pediatric patients with SP bloodstream infection3 months to 13 years oldInvasive21Capsule-quellung testShi et al. 2019124BeijingApr. 2012–Mar. 2017Pediatric inpatients with IPD<14 years oldInvasive111Capsule-quellung testWang et al. 201689BeijingJan. 2013–Apr. 2016Pediatric inpatients with IPD3 months to 7.5 years oldInvasive30Capsule-quellung testYv et al. 201467BeijingMar. 2013–Feb. 2014Pediatric outpatients with upper respiratory infection1 to 16 years oldNon-invasive100Capsule-quellung testDong et al. 201683BeijingMar. 2013–Feb. 2014Pediatric inpatients with PD1 months to 14 yearsNon-invasive + Invasive195Capsule-quellung testLyu et al. 201687BeijingMar. 2013–Feb. 2014Pediatric inpatients with PD<14 years oldNon-invasive + Invasive187Capsule-quellung testLiu et al. 2018105BeijingMar. 2013–Dec. 2017Pediatric inpatients with IPD<15 years oldInvasive67Capsule-quellung testLv et al. 2020136BeijingMar. 2013–Feb. 2019Pediatric patients with pneumococcal infection≤14 years oldNon-invasive + Invasive834Capsule-quellung testWang et al. 201579BeijingNot specifiedPediatric patients with pneumonia≤5 years oldNon-invasive + Invasive30Capsule-quellung testDananche et al. 2020131Beijing2010–2014Pediatric patients>2 months old, <5 years oldNot specified168MPCRWang et al. 2020140Beijing2013–2019Pediatric patients<15 years oldNon-invasive + Invasive903Capsule-quellung testZhu et al. 2020149Beijing2012–2017Pediatric patients with IPD<9 years oldInvasive24Capsule-quellung testXu et al. 2021163BeijingJanuary 2014 –December 2019Pediatric patients<18 years oldInvasive67Capsule-quellung testJiang et al. 2022168BeijingJanuary 2012–December 2017Pediatric patients<18 years oldInvasive64Capsule-quellung testLi et al. 2022170BeijingJanuary 2013–December 2020Pediatric patients<3 years oldInvasive10Capsule-quellung testFan et al. 2023179BeijingJuly 2018–July 2022Beijing Patients5-97 years oldNon-invasive + invasive52PneumoCaT (Pneumococcal Capsular Typing)Zhou et al. 201691Shenyang, LiaoningJan. 2000–Aug. 2014.Pediatric inpatients with IPD≤14 years oldInvasive256Capsule-quellung testLiu et al. 201354Shenyang, LiaoningJan. 2009–Dec. 2011Pediatric inpatients with IPD3 months to less than 5 yearsInvasive61Capsule-quellung testWang et al.201466Dalian, LiaoningJul. 2010–Jun. 2013Pediatric inpatients with pneumonia<5 years oldNon-invasive134MPCRLiu et al. 201576Tianjin, LiaoningOct. 2012–Apr. 2014Patients with clinical infectionNot specifiedNon-invasive72MPCRZhang et al. 2021165Baicheng, JilinJan. 2017–Feb. 2019Pediatric patient<6 years oldNon- invasive101MPCR and DNA sequenceWu et al. 201249Linyi, ShandongJan. 2008–Sep. 2010Pediatric patients with Lower respiratory tract infection10 months to 6 yearsNon-invasive124Capsule-quellung testZhang et al. 201690Jinan, ShandongJan. 2014–Jun. 2015Pediatric patients with eye infectionChildrenNon-invasive42MPCRLi et al. 2018104Qingdao, ShandongJan. 2015–Feb. 2017Pediatric inpatients with PD5 to 82 years oldNon-invasive + Invasive200Using 12 pooled antiseraLi et al. 2020133Shijiazhuang, HebeiJan. 2014–Dec. 2018Pediatric patients with acute otitis media56 days to 15 years oldNon-invasive111MPCRWang et al. 2019125Shijiazhuang, HebeiJan. 2014–Dec. 2018Pediatric inpatients with PD<14 years oldNon-invasive + Invasive416MPCRCao et al. 2020130Shijiazhuang, Hebei2017 –2018Pediatric patients<12 years oldNon-invasive + Invasive107MPCRWang et al. 2022173Hebei Province2014–2018Pediatric patients<18 years oldNon-invasive + Invasive487MPCRLei et al. 2019120Yan’ an, ShaanxiDec. 2013 to Nov. 2016Children with acute otitis media4 to 71 monthsNon-invasive117Capsule-quellung testLiu et al. 2019123Xi’ an, ShaanxiJan. 2014–Dec. 2017Patients with pneumococcal infectionNot specifiedNot specified121Capsule-quellung testTian et al. 2018107Keshi, XinjiangOct. 2015–Feb. 2016Pediatric patients with upper respiratory infection1 months to 5 years oldNon-invasive47Capsule-quellung testTian et al. 2020139Ürümqi, XinjiangJan. 2018 – Dec. 2018Pediatric patients<5 years oldNon-invasive + Invasive225Capsule-quellung testGao et al. 2019115Zhengzhou, HenanJan. 2016–Dec. 2018Pediatric inpatients with IPD.27 days to 13 years oldInvasive108Capsule-quellung testHu et al. 2021152Zhengzhou, HenanJan. 2017 –Dec. 2019Pediatric patients<6 years oldNon-invasive1788Capsule-quellung testWang et al. 2022174Zhengzhou, HenanJun. 2017 –Jun. 2020Premature infants and newborns with low birth weights<1 year oldNot specified9Capsule-quellung testZhang et al. 2022175Kaifeng, Henan2020–2021Pediatric patients<12 years oldNon-invasive + Invasive343Capsule-quellung testZhao et al.2022176Zhengzhou, HenanOct. 2019 – Mar. 2021Pediatric patients<12 years oldNon-invasive + Invasive116Capsule-quellung testZhao et al. 2020148Beijing, Hebei, Shanxi, Liaoning, and ShandongApr. 2016–Oct. 2017Adults and childrenpatients with IPD.1 month −79 years oldInvasive164Capsule-quellung testZhou et al. 2022178Northeast ChinaJan. 2000 – Dec. 2019Patients not identifiedNot specifiedNon-Invasive + Invasive1240Capsule-quellung testSouth China (92 papers)Yang et al. 200122Shanghai1996–1999Patients with Respiratory infectionNot specifiedNon-invasive111Capsule-quellung testZhang et al. 200224ShanghaiAug. 2000–Aug. 2001Pediatric inpatients with respiratory infection<3 years oldNon-invasive + Invasive112Capsule-quellung testWang et al. 200426Shanghai2000–2002Pediatric patients with respiratory infection1 month to 15 years oldNon-invasive111Capsule-quellung testYang et al. 200832Shanghai2004–2005Patients with community-acquired respiratory tractinfectionNot specifiedNon-invasive103Capsule-quellung test + MPCRZhou et al. 2017100Shanghai2006–2012Pediatric inpatients with PD<10 years oldNon-invasive + Invasive169Capsule-quellung test + MPCRZhang et al. 201144ShanghaiOct. 2007–May 2008Pediatric patients with respiratory infection≤5 years oldNon-invasive338Capsule-quellung testJiang et al. 201571ShanghaiJan. 2011–Dec. 2013Community acquired andhospital acquired infections of adults>18 years oldNon-invasive + Invasive37Capsule-quellung test + MPCRPan et al. 201578ShanghaiJan. 2012–Dec. 2012Pediatric patients with NIPD≤14 years oldNon-invasive300Capsule-quellung test + Using 12 pooled antiseraHan et al. 2019116ShanghaiNot specifiedPediatric patients with invasive pneumococcal infection1 to 35 monthsInvasive88Capsule-quellung testLi et al. 2019122Shanghai2015–2017Adult patients with PD>18 years oldNon-invasive + IPD70MPCRWang et al. 2020141ShanghaiMar. 2016–Dec. 2018Pediatric patients with local or systemic infectionsChildren (95.9% of them were younger than 5 years)Non-invasive + Invasive68MPCRZhao et al. 2019129Shanghai2018Community-acquired pneumoniaand healthcare-associated pneumoniaNot specifiedNot specified261MPCRLi et al. 200935Chongqing, Sichuan2003–2008Pediatric patients with IPDChildren (most of them were younger than 5 years)Invasive10Using 12 pooled antiseraDong et al. 201037Chongqing, SichuanJan. 2006–Aug. 2008Patients with pneumococcal diseaseNot specifiedNon-invasive + Invasive143Capsule-quellung testZhang et al. 201252Chongqing, Sichuan2009–2010Patients with suspected cases of pneumococcal disease<5 years or ≥50 years oldNon-invasive + Invasive90Capsule-quellung test + MPCRJing et al. 201686Chongqing, SichuanJan. 2009–Dec. 2014Pediatric outpatients with clinical symptoms of infectionChildrenNon-invasive + Invasive592Capsule-quellung testYv et al. 2019128Chongqing, SichuanJun. 2009–Dec. 2016Children with pneumonia<5 years oldNon-invasive193MPCRLiu et al. 201464Chongqing, Sichuan2010–2013Pediatric IPD<11 years oldInvasive51MPCRZhang et al. 2020145Chongqing, SichuanJan. 2014–Dec. 2017Pediatric patients with Respiratory tract infection≤6 years oldNon-invasive175Using 12 pooled antiseraChen et al. 201682Chongqing, SichuanJan. 2015–Dec. 2015Pediatric patients with respiratory tract infection>1 months but <12 yearsNon-invasive267Capsule-quellung testRen et al. 201040Chengdu, Sichuan2004–2006Pediatric outpatients with pneumoniaChildren (not specifiedNot specified118Capsule-quellung testZhang et al. 2020146Yibin, SichuanMar. 2015–Dec. 2018Infection patientsNot specifiedNon-invasive + Invasive100MPCRPan et al. 201794Luzhou, Sichuan2012–2015Patients with pneumococcal infectionNot specifiedNon-invasive + Invasive302Using 12 pooled antiseraWen et al. 201797Jiangxian, Sichuan2015Pediatric patients with Respiratory tract infection1 month-14 years oldNon-invasive199Capsule-quellung testPeng et al. 2021156Chengdu, SichuanJan. 2018 – Dec. 2018Patients with community acquired pneumoniaAll patients >1 years oldNon-invasive + Invasive78MPCRTang et al. 2021160Deyang, sichuanNov. 2018 – Jun. 2019Pediatric and adult patientsMajority of patients <2 years old or >50 years oldNon-invasive192Capsule-quellung testXiong et al. 2021162Jiangxian, Sichuan2017–2019Pediatric patients with upper respiratory tract infection<6 years oldNon-invasive156Chessboard systemYan et al. 2021164Chengdu, SichuanMar. 2017 – Nov. 2019Pediatric patientsAll patients <14 years oldNon-invasive + Invasive128PneumoCaT (Pneumococcal Capsular Typing)Chen et al. 2022166Chengdu, SichuanJan. 2019 –Jan. 2021Pediatric patients<5 years oldNon-invasive + Invasive100MPCRLi et al. 200223Guangzhou, GuangdongMar. 1999–Jul. 2001Pediatric upper respiratory tract infection2-14 years oldNon-invasive78Capsule-quellung testDeng et al. 200830Guangzhou, GuangdongFeb. 2006–Feb. 2007Pediatric inpatients with pneumonia1 month to 6 years oldNon-invasive79Capsule-quellung testHuang et al. 201569Guangzhou, GuangdongJan. 2011–Jun. 2013Patients with pneumococcal infectionsNot specified (both children and adults)Non-invasive + Invasive94Capsule-quellung test + MPCRChen et al. 201792Guangzhou, GuangdongNov. 2015–Oct. 2016Elder people with pneumococcal infection≥60 years old (60-84)Non-invasive120MPCRZhao et al. 201042Shenzhen, GuangdongFeb. 2006–Feb. 2007Pediatric patients with community required pneumonia≤5 years oldNon-invasive + Invasive90Capsule-quellung testMa et al. 201356Shenzhen, GuangdongJan. 2009–Aug. 2012Pediatric patients with IPD<14 years oldInvasive87Capsule-quellung testJin et al. 201685Shenzhen, GuangdongJan. 2009–Dec. 2013Hospitalized children with pneumococcal infections.Children (most of them <2 years old)Non-invasive + Invasive193MPCRLu et al. 201577Shenzhen, GuangdongFeb. 2010–Aug. 2013Pediatric patients with IPD≤14 years oldInvasive76Capsule-quellung testTan et al. 2020137Shenzhen, GuangdongJan. 2012–Dec. 2018Pediatric patients with IPDChildren (most of them <2 years old)Invasive97Capsule-quellung test + MPCRBao et al. 2019110Shenzhen, GuangdongJan. 2013–May 2017Pediatric patients with IPD<14 years oldInvasive94Capsule-quellung testKong et al. 2019119Shenzhen, GuangdongJun. 2013–Jun. 2018PICU patients with severe Streptococcus pneumoniae pneumoniaChildren (most of them <7 years old)Non-invasive86MPCRLi et al. 201574Zhaoqing, GuangdongJul. 2013–Jun. 1014Pediatric Patients with community-acquired pneumonia1 month-5 years oldNot specified166Capsule-quellung testLi et al. 201573Dongguan, GuangdongJan. 2011–Dec. 2012Hospitalizedand outpatient children with pneumonia<5 years oldNon-invasive229Capsule-quellung testYang et al. 2018108Zhongshan, Guangdong2015Pediatric patients with lower respiratory tract infection≤14 years oldNon-invasive819MPCRYang et al. 201580Guangdong provinceNot specifiedPatients with IPDNot specifiedInvasive143Capsule-quellung testLiang et al. 2020135Zhaoqing, GuangdongApr. 2016 – Dec. 2018Pediatric and adult patients<12 years old, > 50 years oldNon-invasive + invasive190MPCRJiang et al. 2021153Shenzhen, Guangdong2014–2018Pediatric patients<4 years oldInvasive81MPCRLiu et al. 2021155Dongguan, GuangdongNov. 2018 – Dec. 2020Pediatric patients with respiratory tract infection<15 years oldNot specified24Capsule-quellung testLi et al. 2022169Shenzhen, GuangdongJan. 2018 – Dec. 2018Pediatric patients with severe pneumonia<15 years oldNon-invasive43MPCRLin et al. 201575Wenzhou, ZhejiangJan. 2009–May 2013Patients with IPDNot specifiedNon-invasive + Invasive52Capsule-quellung testZhang et al. 2020144Wenzhou, ZhejiangJan.–Aug. 2010Pediatric inpatients with lung infection2 months to 5 yearsNon-invasive51Capsule-quellung testChen et al. 2019111Pujiang, ZhejiangJan. 2013–Aug. 2018Pediatric patients with SP infection7-14 years oldNon-invasive + Invasive126Capsule-quellung testWang et al. 201796Wenling, ZhejiangOct. 2011–May 2014Pediatric patients infected with SP≤107 months oldNon-invasive + Invasive284Capsule-quellung testLi et al. 201248Hangzhou, Zhejiang2009Pediatric patients with PDChildrenNon-invasive + Invasive106Capsule-quellung testJiang et al, 2019118Yiwu, ZhejiangDec. 2013–Nov. 2017Pediatric inpatients with respiratory tract infection<5 years oldNon-invasive212MPCRYing et al. 201251Shaoxing, Zhejiang2009–2010Patients with PDChildren (0-5 years old) and AdultNon-invasive + Invasive103Capsule-quellung testXiong et al. 2020143Wenzhou, Zhejiang2012–2016Not identifiedNot identifiedNon-invasive + Invasive111MPCRSong et al. 2021158ChunAn, ZhejiangAug. 2019 – Nov. 2019patients receiving mechanical ventilation in ICUNot specifiedNon-invasive101Capsule-quellung testSong et al. 2021159Hangzhou, ZhejiangJan. 2018 – Jun. 2019Pediatric patients<3 years oldNot specified57MPCRWu et al. 2021161Shaoxing, ZhejiangOct. 2015 – May. 2019Adult COPD patients58-79 years oldNon-invasive + Invasive273Capsule-quellung testQi et al. 200425Suzhou, JiangsuSep. 2002–May 2003Pediatric patients with lower respiratory infection<5 years oldNon-invasive42Capsule-quellung testGeng et al. 201461Suzhou, JiangsuMar.2006–Mar. 2007Pediatric inpatients with respiratory infection<3 years oldNon-invasive48Capsule-quellung test + MPCRChen et al. 201036Suzhou, Jiangsu2007Pediatric inpatients with pneumonia and/or any other upper respiratory infections<3 years oldNot specified31Not specifiedZhang et al. 201798Suzhou, JiangsuJan. 2010–Dec. 2015Pediatric invasive pneumococcal diseases<15 years oldInvasive80Capsule-quellung test + MPCRDing et al. 201568Suzhou, JiangsuJan. 2011–Dec. 2013Pediatric patients with acute otitis media<18 years ageNon-invasive108MPCRShi et al. 2018106Suzhou, JiangsuJan. 2011–Dec. 2016Pediatric patients with meningitis0.64 to 2.31 years oldInvasive39Capsule-quellung test + MPCRGeng et al. 201462Suzhou, JiangsuJuly 2012–July 2013Pediatric inpatients with respiratory infection≤5 years oldNon-invasive175MPCRChen et al. 2019112Suzhou, Jiangsu2013–2015Pediatric patients with PD<12 years oldNon-invasive + Invasive250Capsule-quellung testDai et al. 2019113Suzhou, JiangsuJan. 2017–May 2018Pediatric patients with PD8-41 months oldNon-invasive + Invasive528Capsule-quellung testLi et al. 2019121Xvzhou, JiangsuJan. 2017–Oct. 2018Outpatients with upper respiratory tract infection30 days to 7 years oldNon-invasive171Capsule-quellung testPan et al. 201465Nanjing, JiangsuJan. 2005–Dec. 2012Pediatric patients with IPDChildrenInvasive155Capsule-quellung testXv et al. 201250Nanjing, JiangsuJan. 2007–Dec. 2010Pediatric patients with IPDChildrenInvasive48Capsule-quellung testMiao et al. 201688Nanjing, JiangsuNov. 2007–Jul. 2011Pediatric patients with IPDChildrenInvasive56MPCRZhong et al. 201360Nanjing, JiangsuNov. 2007–Jul.2011Pediatric patients with IPD2 days to 13 years oldInvasive47MPCRZhou et al. 201581Nanjing, JiangsuJan. 2009–Dec. 2013Pediatric patients with IPDChildren (most of them <2 years old)Invasive51Capsule-quellung testLi et al. 201463Nanjing, Jiangsu2012Pediatric inpatients with respiratory infection1-10 years oldNon-invasive584Capsule-quellung testHan et al. 2019117Nanjing, JiangsuJan. 2015–Apr. 2018Pediatric patients with SP infection1 month to 7 years oldNon-invasive224Capsule-quellung testWu et al. 2020142Suzhou, JiangsuJan. 2011 – Dec. 2017Pediatric patients<12 years oldInvasive97Quellung reaction with antiseraChen et al. 2021150Suzhou, JiangsuJan. 2010 – Dec. 2017Pediatric patients<5 years oldInvasive74Quellung reaction with antisera or MPCRLin et al. 2022171Suzhou, JiangsuJan. 2017 – Jun 2019Pediatric patients with PV13 vaccination<3 years oldNon-invasive + Invasive666Cheeseboard + quellung reactionLiang et al. 201793Liuzhou, GuangxiOct. 2015–Sep. 2016Pediatric inpatients with fever≤12 years oldNot specified87Capsule-quellung test + MPCRLi et al. 2018103Liuzhou, GuangxiDec. 2015–Jan. 2017Pediatric inpatients with infective symptoms≤5 years oldNon-invasive + Invasive537MPCRFu et al. 2019114Liuzhou, GuangxiJan. 2016–Jun. 2016Pediatric patients with acute otitis media<18 years oldNon-invasive37MPCRTan et al. 2020138Nanning, Guangxi2014–2019Pediatric patients<12 years oldInvasive117Capsule-quellung testLiang et al. 2021154Liuzhou, GuangxiJan. 2015 – Jan. 2017Pediatric patients<5 years oldNot specified419MPCRQiu et al. 2022172Yulin, GuangxiJan. 2015 – Dec. 2019Pediatric and adult patientsMajority of patients under 5 years oldNon-invasive + Invasive150MPCRShen et al. 201795Zunyi, GuizhouJan. 2014–Dec. 2016.Inpatients suspected of having a bacterial infectionNot specifiedNon-invasive + Invasive778MPCRYe et al. 2019127Kunming, YunnanJan. 2016–Dec. 2017Pediatric patients with respiratory tract infection1-12 years oldNot specified240Capsule-quellung testZhang et al. 201145Yiyang, Hunan provinceJan. 2004–Dec. 2009Adult inpatients with pneumoniaAdultsNon-invasive + Invasive822Capsule-quellung testJiang et al. 2018102Jingzhou, HubeiApr. 2010–Sep. 2012Inpatients with IPDBoth children and adultsNon-invasive + Invasive16Capsule-quellung testHuang et al. 201570Xiamen, FujianJan. 2012–dec. 2013Inpatients with PDBoth children and adultsNon-invasive + Invasive265Using 12 pooled antiseraChen et al. 2021151Quanzhou, Fujian2013–2016Pediatric and Adult patientsMost patients under 5 years oldNon-invasive + Invasive101MPCRYan et al. 201912614 cities of southwest ChinaFeb. 2016 to Feb. 2018Pediatric patients with SP infection<12 years oldNon-invasive + Invasive102MPCRNational (20 papers)Yao et al. 200728Three hospitals in three cities (Beijing, Shanghai, and Guangzhou)2000–2002Children with acute respiratory infections<5 years oldNon-invasive625Capsule-quellung testLiu et al. 200831Nine study centers in 8 cities (Beijing, Shanghai, Shenzhen, Chengdu, Nanjing, Wuhan, Shenyang, and Hangzhou)Jan. 2005–Dec. 2006Pediatric patients with PD<4 years oldNon-invasive + Invasive451Capsule-quellung testLiu et al. 201038Seventeen hospitals in 15 regionsJan. 2005–Aug. 2008Patients with IPD4 days to 86 years oldInvasive148Capsule-quellung testXiao et al. 201041Thirteen hospitals across ChinaJan. 2005–Dec. 2008Patients with IPDBoth children and adultsInvasive41Capsule-quellung testZhao et al. 201359Twelve cities throughout China2005–2011Pediatric and adult patients with pneumococcal infectionsBoth children and adultsInvasive240Capsule-quellung testYao et al. 200833Four hospitals in four cities (Beijing, Shanghai, Shenzhen, and Guangzhou)Feb. 2006–Feb. 2007Pediatric inpatients with pneumonia≤5 years oldNon-invasive279Capsule-quellung testYao et al. 201143Five hospitals in five cities (Beijing, Shanghai, Shenzhen, Tianjin, and Guangzhou)Feb. 2006–Feb. 2008.Pediatric inpatients with pneumonia≤5 years oldNon-invasive338Capsule-quellung testMa et al. 201355Eleven hospitals in different regions of ChinaJan. 2006–Dec. 2008Pediatric patients with IDP<14 years oldInvasive164Capsule-quellung testZhang et al. 201358Eighteen hospitals across ChinaJun. 2007–May 2011Patients with pneumococcal infectionsBoth children and adultsNon-invasive39Capsule-quellung test + MPCRKim et al. 201247Fourteen hospitals in eight citiesMar. 2008–Dec. 2009Patients with pneumococcal infectionsPatients with mean age of 34.4 yearsNon-invasive + Invasive624Capsule-quellung testDu et al. 201246Ten teaching hospitals across ChinaJan. 2009–Jan. 2010Patients with community-acquired respiratory tract infection14-101 years oldNon-invasive43Capsule-quellung test + MPCRWang et al. 201357Thirteen hospitals in ten citiesJan. 2010–Dec. 2011Patients with PDBoth children and adultsNon-invasive + Invasive471Capsule-quellung test+ Using 12 pooled antiseraZhao et al. 201799Twenty teaching hospitals in 17 different cities2011–2016Pediatric and adult patients with pneumococcal infectionsBoth children and adultsNon-invasive + Invasive881Capsule-quellung testLi et al. 2020134Twenty-seven tertiary hospitals in China2012–2015Patients with IPDBoth children and adultsInvasive269Capsule-quellung testZhu et al. 2018109Eighteen medical centers across ChinaJan. 2012–Dec. 2017Pediatric patients with IPD1 day to 16 years oldInvasive81Capsule-quellung testKim et al. 2020132Eight hospitals in ChinaDec. 2012–Jul. 2017Adult patients with IPD or pneumonia>50 years oldNon-invasive + Invasive208Capsule-quellung testZhao et al. 2020147Beijing, Hebei, Shanxi, Liaoning, and ShandongApr. 2016 – Oct. 2017Pediatric and adult patients with IPDMost patients <5 years oldInvasive164Chessboard systemRen et al. 2021157Throughout China2011–2014Patients not identifiedPatients not identifiedInvasive102Capsule-quellung test + MPCRHuang et al. 2022167Seven Eastern Chinese hospitals2021Pediatric and Adult patientsMost patients <5 years oldNon-invasive + Invasive279MPCRZhou et al. 2022177various locations in China2010–2015Pediatric and Adult patientsaverage age: 46 ± 26.69 yearsInvasive299Capsule-quellung testAbbreviation: Sp, Streptococcal pneumoniae; PD, pneumococcal disease; IPD, invasive pneumococcal disease; NIPD, noninvasive pneumococcal disease; MPCR, multiple polymerase chain reaction. Table 1.Characteristics of 159 included studies.Author, publication yearStudy locationStudy periodTarget populationAgeStrain sourcesTotal tested strainsSerotyping methodNorth China (47 papers)Yv et al. 200021BeijingNov.–Dec.1997Pediatric patients with upper respiratory infection3 months to 5 years oldNon–invasive190Capsule-quellung testLiu et al. 201039Beijing1997–2007Pediatric outpatients with upper respiratory infection<5 years oldNon-invasive893Capsule-quellung testYao et al. 200729Beijing2000–2004pediatric outpatients with upper respiratory infection≤5 years oldNon-invasive129Using 12 pooled antiseraYv et al. 200834Beijing2000–2005Pediatric patients with acute upper respiratory infection<5 years oldNon-invasive519Capsule-quellung testTong et al. 200727Beijing2004Pediatric patients with acute upper respiratory infection≤5 years oldNon-invasive137Capsule-quellung testZhou et al. 201253Beijing2010Pediatric patients with upper respiratory infections<5 years oldNon-invasive135Capsule-quellung testGuo et al. 201684BeijingJan.2010–Dec. 2014Pediatric inpatients with bacteria meningitis<16 years oldNon-invasive12Capsule-quellung testLi et al. 201572BeijingJan. 2012–Mar. 2014Pediatric inpatients with IPDChildrenInvasive21Capsule-quellung test + Using 12 pooled antiseraZhu et al. 2017101BeijingFeb. 2012–Jul. 2014Pediatric patients with SP bloodstream infection3 months to 13 years oldInvasive21Capsule-quellung testShi et al. 2019124BeijingApr. 2012–Mar. 2017Pediatric inpatients with IPD<14 years oldInvasive111Capsule-quellung testWang et al. 201689BeijingJan. 2013–Apr. 2016Pediatric inpatients with IPD3 months to 7.5 years oldInvasive30Capsule-quellung testYv et al. 201467BeijingMar. 2013–Feb. 2014Pediatric outpatients with upper respiratory infection1 to 16 years oldNon-invasive100Capsule-quellung testDong et al. 201683BeijingMar. 2013–Feb. 2014Pediatric inpatients with PD1 months to 14 yearsNon-invasive + Invasive195Capsule-quellung testLyu et al. 201687BeijingMar. 2013–Feb. 2014Pediatric inpatients with PD<14 years oldNon-invasive + Invasive187Capsule-quellung testLiu et al. 2018105BeijingMar. 2013–Dec. 2017Pediatric inpatients with IPD<15 years oldInvasive67Capsule-quellung testLv et al. 2020136BeijingMar. 2013–Feb. 2019Pediatric patients with pneumococcal infection≤14 years oldNon-invasive + Invasive834Capsule-quellung testWang et al. 201579BeijingNot specifiedPediatric patients with pneumonia≤5 years oldNon-invasive + Invasive30Capsule-quellung testDananche et al. 2020131Beijing2010–2014Pediatric patients>2 months old, <5 years oldNot specified168MPCRWang et al. 2020140Beijing2013–2019Pediatric patients<15 years oldNon-invasive + Invasive903Capsule-quellung testZhu et al. 2020149Beijing2012–2017Pediatric patients with IPD<9 years oldInvasive24Capsule-quellung testXu et al. 2021163BeijingJanuary 2014 –December 2019Pediatric patients<18 years oldInvasive67Capsule-quellung testJiang et al. 2022168BeijingJanuary 2012–December 2017Pediatric patients<18 years oldInvasive64Capsule-quellung testLi et al. 2022170BeijingJanuary 2013–December 2020Pediatric patients<3 years oldInvasive10Capsule-quellung testFan et al. 2023179BeijingJuly 2018–July 2022Beijing Patients5-97 years oldNon-invasive + invasive52PneumoCaT (Pneumococcal Capsular Typing)Zhou et al. 201691Shenyang, LiaoningJan. 2000–Aug. 2014.Pediatric inpatients with IPD≤14 years oldInvasive256Capsule-quellung testLiu et al. 201354Shenyang, LiaoningJan. 2009–Dec. 2011Pediatric inpatients with IPD3 months to less than 5 yearsInvasive61Capsule-quellung testWang et al.201466Dalian, LiaoningJul. 2010–Jun. 2013Pediatric inpatients with pneumonia<5 years oldNon-invasive134MPCRLiu et al. 201576Tianjin, LiaoningOct. 2012–Apr. 2014Patients with clinical infectionNot specifiedNon-invasive72MPCRZhang et al. 2021165Baicheng, JilinJan. 2017–Feb. 2019Pediatric patient<6 years oldNon- invasive101MPCR and DNA sequenceWu et al. 201249Linyi, ShandongJan. 2008–Sep. 2010Pediatric patients with Lower respiratory tract infection10 months to 6 yearsNon-invasive124Capsule-quellung testZhang et al. 201690Jinan, ShandongJan. 2014–Jun. 2015Pediatric patients with eye infectionChildrenNon-invasive42MPCRLi et al. 2018104Qingdao, ShandongJan. 2015–Feb. 2017Pediatric inpatients with PD5 to 82 years oldNon-invasive + Invasive200Using 12 pooled antiseraLi et al. 2020133Shijiazhuang, HebeiJan. 2014–Dec. 2018Pediatric patients with acute otitis media56 days to 15 years oldNon-invasive111MPCRWang et al. 2019125Shijiazhuang, HebeiJan. 2014–Dec. 2018Pediatric inpatients with PD<14 years oldNon-invasive + Invasive416MPCRCao et al. 2020130Shijiazhuang, Hebei2017 –2018Pediatric patients<12 years oldNon-invasive + Invasive107MPCRWang et al. 2022173Hebei Province2014–2018Pediatric patients<18 years oldNon-invasive + Invasive487MPCRLei et al. 2019120Yan’ an, ShaanxiDec. 2013 to Nov. 2016Children with acute otitis media4 to 71 monthsNon-invasive117Capsule-quellung testLiu et al. 2019123Xi’ an, ShaanxiJan. 2014–Dec. 2017Patients with pneumococcal infectionNot specifiedNot specified121Capsule-quellung testTian et al. 2018107Keshi, XinjiangOct. 2015–Feb. 2016Pediatric patients with upper respiratory infection1 months to 5 years oldNon-invasive47Capsule-quellung testTian et al. 2020139Ürümqi, XinjiangJan. 2018 – Dec. 2018Pediatric patients<5 years oldNon-invasive + Invasive225Capsule-quellung testGao et al. 2019115Zhengzhou, HenanJan. 2016–Dec. 2018Pediatric inpatients with IPD.27 days to 13 years oldInvasive108Capsule-quellung testHu et al. 2021152Zhengzhou, HenanJan. 2017 –Dec. 2019Pediatric patients<6 years oldNon-invasive1788Capsule-quellung testWang et al. 2022174Zhengzhou, HenanJun. 2017 –Jun. 2020Premature infants and newborns with low birth weights<1 year oldNot specified9Capsule-quellung testZhang et al. 2022175Kaifeng, Henan2020–2021Pediatric patients<12 years oldNon-invasive + Invasive343Capsule-quellung testZhao et al.2022176Zhengzhou, HenanOct. 2019 – Mar. 2021Pediatric patients<12 years oldNon-invasive + Invasive116Capsule-quellung testZhao et al. 2020148Beijing, Hebei, Shanxi, Liaoning, and ShandongApr. 2016–Oct. 2017Adults and childrenpatients with IPD.1 month −79 years oldInvasive164Capsule-quellung testZhou et al. 2022178Northeast ChinaJan. 2000 – Dec. 2019Patients not identifiedNot specifiedNon-Invasive + Invasive1240Capsule-quellung testSouth China (92 papers)Yang et al. 200122Shanghai1996–1999Patients with Respiratory infectionNot specifiedNon-invasive111Capsule-quellung testZhang et al. 200224ShanghaiAug. 2000–Aug. 2001Pediatric inpatients with respiratory infection<3 years oldNon-invasive + Invasive112Capsule-quellung testWang et al. 200426Shanghai2000–2002Pediatric patients with respiratory infection1 month to 15 years oldNon-invasive111Capsule-quellung testYang et al. 200832Shanghai2004–2005Patients with community-acquired respiratory tractinfectionNot specifiedNon-invasive103Capsule-quellung test + MPCRZhou et al. 2017100Shanghai2006–2012Pediatric inpatients with PD<10 years oldNon-invasive + Invasive169Capsule-quellung test + MPCRZhang et al. 201144ShanghaiOct. 2007–May 2008Pediatric patients with respiratory infection≤5 years oldNon-invasive338Capsule-quellung testJiang et al. 201571ShanghaiJan. 2011–Dec. 2013Community acquired andhospital acquired infections of adults>18 years oldNon-invasive + Invasive37Capsule-quellung test + MPCRPan et al. 201578ShanghaiJan. 2012–Dec. 2012Pediatric patients with NIPD≤14 years oldNon-invasive300Capsule-quellung test + Using 12 pooled antiseraHan et al. 2019116ShanghaiNot specifiedPediatric patients with invasive pneumococcal infection1 to 35 monthsInvasive88Capsule-quellung testLi et al. 2019122Shanghai2015–2017Adult patients with PD>18 years oldNon-invasive + IPD70MPCRWang et al. 2020141ShanghaiMar. 2016–Dec. 2018Pediatric patients with local or systemic infectionsChildren (95.9% of them were younger than 5 years)Non-invasive + Invasive68MPCRZhao et al. 2019129Shanghai2018Community-acquired pneumoniaand healthcare-associated pneumoniaNot specifiedNot specified261MPCRLi et al. 200935Chongqing, Sichuan2003–2008Pediatric patients with IPDChildren (most of them were younger than 5 years)Invasive10Using 12 pooled antiseraDong et al. 201037Chongqing, SichuanJan. 2006–Aug. 2008Patients with pneumococcal diseaseNot specifiedNon-invasive + Invasive143Capsule-quellung testZhang et al. 201252Chongqing, Sichuan2009–2010Patients with suspected cases of pneumococcal disease<5 years or ≥50 years oldNon-invasive + Invasive90Capsule-quellung test + MPCRJing et al. 201686Chongqing, SichuanJan. 2009–Dec. 2014Pediatric outpatients with clinical symptoms of infectionChildrenNon-invasive + Invasive592Capsule-quellung testYv et al. 2019128Chongqing, SichuanJun. 2009–Dec. 2016Children with pneumonia<5 years oldNon-invasive193MPCRLiu et al. 201464Chongqing, Sichuan2010–2013Pediatric IPD<11 years oldInvasive51MPCRZhang et al. 2020145Chongqing, SichuanJan. 2014–Dec. 2017Pediatric patients with Respiratory tract infection≤6 years oldNon-invasive175Using 12 pooled antiseraChen et al. 201682Chongqing, SichuanJan. 2015–Dec. 2015Pediatric patients with respiratory tract infection>1 months but <12 yearsNon-invasive267Capsule-quellung testRen et al. 201040Chengdu, Sichuan2004–2006Pediatric outpatients with pneumoniaChildren (not specifiedNot specified118Capsule-quellung testZhang et al. 2020146Yibin, SichuanMar. 2015–Dec. 2018Infection patientsNot specifiedNon-invasive + Invasive100MPCRPan et al. 201794Luzhou, Sichuan2012–2015Patients with pneumococcal infectionNot specifiedNon-invasive + Invasive302Using 12 pooled antiseraWen et al. 201797Jiangxian, Sichuan2015Pediatric patients with Respiratory tract infection1 month-14 years oldNon-invasive199Capsule-quellung testPeng et al. 2021156Chengdu, SichuanJan. 2018 – Dec. 2018Patients with community acquired pneumoniaAll patients >1 years oldNon-invasive + Invasive78MPCRTang et al. 2021160Deyang, sichuanNov. 2018 – Jun. 2019Pediatric and adult patientsMajority of patients <2 years old or >50 years oldNon-invasive192Capsule-quellung testXiong et al. 2021162Jiangxian, Sichuan2017–2019Pediatric patients with upper respiratory tract infection<6 years oldNon-invasive156Chessboard systemYan et al. 2021164Chengdu, SichuanMar. 2017 – Nov. 2019Pediatric patientsAll patients <14 years oldNon-invasive + Invasive128PneumoCaT (Pneumococcal Capsular Typing)Chen et al. 2022166Chengdu, SichuanJan. 2019 –Jan. 2021Pediatric patients<5 years oldNon-invasive + Invasive100MPCRLi et al. 200223Guangzhou, GuangdongMar. 1999–Jul. 2001Pediatric upper respiratory tract infection2-14 years oldNon-invasive78Capsule-quellung testDeng et al. 200830Guangzhou, GuangdongFeb. 2006–Feb. 2007Pediatric inpatients with pneumonia1 month to 6 years oldNon-invasive79Capsule-quellung testHuang et al. 201569Guangzhou, GuangdongJan. 2011–Jun. 2013Patients with pneumococcal infectionsNot specified (both children and adults)Non-invasive + Invasive94Capsule-quellung test + MPCRChen et al. 201792Guangzhou, GuangdongNov. 2015–Oct. 2016Elder people with pneumococcal infection≥60 years old (60-84)Non-invasive120MPCRZhao et al. 201042Shenzhen, GuangdongFeb. 2006–Feb. 2007Pediatric patients with community required pneumonia≤5 years oldNon-invasive + Invasive90Capsule-quellung testMa et al. 201356Shenzhen, GuangdongJan. 2009–Aug. 2012Pediatric patients with IPD<14 years oldInvasive87Capsule-quellung testJin et al. 201685Shenzhen, GuangdongJan. 2009–Dec. 2013Hospitalized children with pneumococcal infections.Children (most of them <2 years old)Non-invasive + Invasive193MPCRLu et al. 201577Shenzhen, GuangdongFeb. 2010–Aug. 2013Pediatric patients with IPD≤14 years oldInvasive76Capsule-quellung testTan et al. 2020137Shenzhen, GuangdongJan. 2012–Dec. 2018Pediatric patients with IPDChildren (most of them <2 years old)Invasive97Capsule-quellung test + MPCRBao et al. 2019110Shenzhen, GuangdongJan. 2013–May 2017Pediatric patients with IPD<14 years oldInvasive94Capsule-quellung testKong et al. 2019119Shenzhen, GuangdongJun. 2013–Jun. 2018PICU patients with severe Streptococcus pneumoniae pneumoniaChildren (most of them <7 years old)Non-invasive86MPCRLi et al. 201574Zhaoqing, GuangdongJul. 2013–Jun. 1014Pediatric Patients with community-acquired pneumonia1 month-5 years oldNot specified166Capsule-quellung testLi et al. 201573Dongguan, GuangdongJan. 2011–Dec. 2012Hospitalizedand outpatient children with pneumonia<5 years oldNon-invasive229Capsule-quellung testYang et al. 2018108Zhongshan, Guangdong2015Pediatric patients with lower respiratory tract infection≤14 years oldNon-invasive819MPCRYang et al. 201580Guangdong provinceNot specifiedPatients with IPDNot specifiedInvasive143Capsule-quellung testLiang et al. 2020135Zhaoqing, GuangdongApr. 2016 – Dec. 2018Pediatric and adult patients<12 years old, > 50 years oldNon-invasive + invasive190MPCRJiang et al. 2021153Shenzhen, Guangdong2014–2018Pediatric patients<4 years oldInvasive81MPCRLiu et al. 2021155Dongguan, GuangdongNov. 2018 – Dec. 2020Pediatric patients with respiratory tract infection<15 years oldNot specified24Capsule-quellung testLi et al. 2022169Shenzhen, GuangdongJan. 2018 – Dec. 2018Pediatric patients with severe pneumonia<15 years oldNon-invasive43MPCRLin et al. 201575Wenzhou, ZhejiangJan. 2009–May 2013Patients with IPDNot specifiedNon-invasive + Invasive52Capsule-quellung testZhang et al. 2020144Wenzhou, ZhejiangJan.–Aug. 2010Pediatric inpatients with lung infection2 months to 5 yearsNon-invasive51Capsule-quellung testChen et al. 2019111Pujiang, ZhejiangJan. 2013–Aug. 2018Pediatric patients with SP infection7-14 years oldNon-invasive + Invasive126Capsule-quellung testWang et al. 201796Wenling, ZhejiangOct. 2011–May 2014Pediatric patients infected with SP≤107 months oldNon-invasive + Invasive284Capsule-quellung testLi et al. 201248Hangzhou, Zhejiang2009Pediatric patients with PDChildrenNon-invasive + Invasive106Capsule-quellung testJiang et al, 2019118Yiwu, ZhejiangDec. 2013–Nov. 2017Pediatric inpatients with respiratory tract infection<5 years oldNon-invasive212MPCRYing et al. 201251Shaoxing, Zhejiang2009–2010Patients with PDChildren (0-5 years old) and AdultNon-invasive + Invasive103Capsule-quellung testXiong et al. 2020143Wenzhou, Zhejiang2012–2016Not identifiedNot identifiedNon-invasive + Invasive111MPCRSong et al. 2021158ChunAn, ZhejiangAug. 2019 – Nov. 2019patients receiving mechanical ventilation in ICUNot specifiedNon-invasive101Capsule-quellung testSong et al. 2021159Hangzhou, ZhejiangJan. 2018 – Jun. 2019Pediatric patients<3 years oldNot specified57MPCRWu et al. 2021161Shaoxing, ZhejiangOct. 2015 – May. 2019Adult COPD patients58-79 years oldNon-invasive + Invasive273Capsule-quellung testQi et al. 200425Suzhou, JiangsuSep. 2002–May 2003Pediatric patients with lower respiratory infection<5 years oldNon-invasive42Capsule-quellung testGeng et al. 201461Suzhou, JiangsuMar.2006–Mar. 2007Pediatric inpatients with respiratory infection<3 years oldNon-invasive48Capsule-quellung test + MPCRChen et al. 201036Suzhou, Jiangsu2007Pediatric inpatients with pneumonia and/or any other upper respiratory infections<3 years oldNot specified31Not specifiedZhang et al. 201798Suzhou, JiangsuJan. 2010–Dec. 2015Pediatric invasive pneumococcal diseases<15 years oldInvasive80Capsule-quellung test + MPCRDing et al. 201568Suzhou, JiangsuJan. 2011–Dec. 2013Pediatric patients with acute otitis media<18 years ageNon-invasive108MPCRShi et al. 2018106Suzhou, JiangsuJan. 2011–Dec. 2016Pediatric patients with meningitis0.64 to 2.31 years oldInvasive39Capsule-quellung test + MPCRGeng et al. 201462Suzhou, JiangsuJuly 2012–July 2013Pediatric inpatients with respiratory infection≤5 years oldNon-invasive175MPCRChen et al. 2019112Suzhou, Jiangsu2013–2015Pediatric patients with PD<12 years oldNon-invasive + Invasive250Capsule-quellung testDai et al. 2019113Suzhou, JiangsuJan. 2017–May 2018Pediatric patients with PD8-41 months oldNon-invasive + Invasive528Capsule-quellung testLi et al. 2019121Xvzhou, JiangsuJan. 2017–Oct. 2018Outpatients with upper respiratory tract infection30 days to 7 years oldNon-invasive171Capsule-quellung testPan et al. 201465Nanjing, JiangsuJan. 2005–Dec. 2012Pediatric patients with IPDChildrenInvasive155Capsule-quellung testXv et al. 201250Nanjing, JiangsuJan. 2007–Dec. 2010Pediatric patients with IPDChildrenInvasive48Capsule-quellung testMiao et al. 201688Nanjing, JiangsuNov. 2007–Jul. 2011Pediatric patients with IPDChildrenInvasive56MPCRZhong et al. 201360Nanjing, JiangsuNov. 2007–Jul.2011Pediatric patients with IPD2 days to 13 years oldInvasive47MPCRZhou et al. 201581Nanjing, JiangsuJan. 2009–Dec. 2013Pediatric patients with IPDChildren (most of them <2 years old)Invasive51Capsule-quellung testLi et al. 201463Nanjing, Jiangsu2012Pediatric inpatients with respiratory infection1-10 years oldNon-invasive584Capsule-quellung testHan et al. 2019117Nanjing, JiangsuJan. 2015–Apr. 2018Pediatric patients with SP infection1 month to 7 years oldNon-invasive224Capsule-quellung testWu et al. 2020142Suzhou, JiangsuJan. 2011 – Dec. 2017Pediatric patients<12 years oldInvasive97Quellung reaction with antiseraChen et al. 2021150Suzhou, JiangsuJan. 2010 – Dec. 2017Pediatric patients<5 years oldInvasive74Quellung reaction with antisera or MPCRLin et al. 2022171Suzhou, JiangsuJan. 2017 – Jun 2019Pediatric patients with PV13 vaccination<3 years oldNon-invasive + Invasive666Cheeseboard + quellung reactionLiang et al. 201793Liuzhou, GuangxiOct. 2015–Sep. 2016Pediatric inpatients with fever≤12 years oldNot specified87Capsule-quellung test + MPCRLi et al. 2018103Liuzhou, GuangxiDec. 2015–Jan. 2017Pediatric inpatients with infective symptoms≤5 years oldNon-invasive + Invasive537MPCRFu et al. 2019114Liuzhou, GuangxiJan. 2016–Jun. 2016Pediatric patients with acute otitis media<18 years oldNon-invasive37MPCRTan et al. 2020138Nanning, Guangxi2014–2019Pediatric patients<12 years oldInvasive117Capsule-quellung testLiang et al. 2021154Liuzhou, GuangxiJan. 2015 – Jan. 2017Pediatric patients<5 years oldNot specified419MPCRQiu et al. 2022172Yulin, GuangxiJan. 2015 – Dec. 2019Pediatric and adult patientsMajority of patients under 5 years oldNon-invasive + Invasive150MPCRShen et al. 201795Zunyi, GuizhouJan. 2014–Dec. 2016.Inpatients suspected of having a bacterial infectionNot specifiedNon-invasive + Invasive778MPCRYe et al. 2019127Kunming, YunnanJan. 2016–Dec. 2017Pediatric patients with respiratory tract infection1-12 years oldNot specified240Capsule-quellung testZhang et al. 201145Yiyang, Hunan provinceJan. 2004–Dec. 2009Adult inpatients with pneumoniaAdultsNon-invasive + Invasive822Capsule-quellung testJiang et al. 2018102Jingzhou, HubeiApr. 2010–Sep. 2012Inpatients with IPDBoth children and adultsNon-invasive + Invasive16Capsule-quellung testHuang et al. 201570Xiamen, FujianJan. 2012–dec. 2013Inpatients with PDBoth children and adultsNon-invasive + Invasive265Using 12 pooled antiseraChen et al. 2021151Quanzhou, Fujian2013–2016Pediatric and Adult patientsMost patients under 5 years oldNon-invasive + Invasive101MPCRYan et al. 201912614 cities of southwest ChinaFeb. 2016 to Feb. 2018Pediatric patients with SP infection<12 years oldNon-invasive + Invasive102MPCRNational (20 papers)Yao et al. 200728Three hospitals in three cities (Beijing, Shanghai, and Guangzhou)2000–2002Children with acute respiratory infections<5 years oldNon-invasive625Capsule-quellung testLiu et al. 200831Nine study centers in 8 cities (Beijing, Shanghai, Shenzhen, Chengdu, Nanjing, Wuhan, Shenyang, and Hangzhou)Jan. 2005–Dec. 2006Pediatric patients with PD<4 years oldNon-invasive + Invasive451Capsule-quellung testLiu et al. 201038Seventeen hospitals in 15 regionsJan. 2005–Aug. 2008Patients with IPD4 days to 86 years oldInvasive148Capsule-quellung testXiao et al. 201041Thirteen hospitals across ChinaJan. 2005–Dec. 2008Patients with IPDBoth children and adultsInvasive41Capsule-quellung testZhao et al. 201359Twelve cities throughout China2005–2011Pediatric and adult patients with pneumococcal infectionsBoth children and adultsInvasive240Capsule-quellung testYao et al. 200833Four hospitals in four cities (Beijing, Shanghai, Shenzhen, and Guangzhou)Feb. 2006–Feb. 2007Pediatric inpatients with pneumonia≤5 years oldNon-invasive279Capsule-quellung testYao et al. 201143Five hospitals in five cities (Beijing, Shanghai, Shenzhen, Tianjin, and Guangzhou)Feb. 2006–Feb. 2008.Pediatric inpatients with pneumonia≤5 years oldNon-invasive338Capsule-quellung testMa et al. 201355Eleven hospitals in different regions of ChinaJan. 2006–Dec. 2008Pediatric patients with IDP<14 years oldInvasive164Capsule-quellung testZhang et al. 201358Eighteen hospitals across ChinaJun. 2007–May 2011Patients with pneumococcal infectionsBoth children and adultsNon-invasive39Capsule-quellung test + MPCRKim et al. 201247Fourteen hospitals in eight citiesMar. 2008–Dec. 2009Patients with pneumococcal infectionsPatients with mean age of 34.4 yearsNon-invasive + Invasive624Capsule-quellung testDu et al. 201246Ten teaching hospitals across ChinaJan. 2009–Jan. 2010Patients with community-acquired respiratory tract infection14-101 years oldNon-invasive43Capsule-quellung test + MPCRWang et al. 201357Thirteen hospitals in ten citiesJan. 2010–Dec. 2011Patients with PDBoth children and adultsNon-invasive + Invasive471Capsule-quellung test+ Using 12 pooled antiseraZhao et al. 201799Twenty teaching hospitals in 17 different cities2011–2016Pediatric and adult patients with pneumococcal infectionsBoth children and adultsNon-invasive + Invasive881Capsule-quellung testLi et al. 2020134Twenty-seven tertiary hospitals in China2012–2015Patients with IPDBoth children and adultsInvasive269Capsule-quellung testZhu et al. 2018109Eighteen medical centers across ChinaJan. 2012–Dec. 2017Pediatric patients with IPD1 day to 16 years oldInvasive81Capsule-quellung testKim et al. 2020132Eight hospitals in ChinaDec. 2012–Jul. 2017Adult patients with IPD or pneumonia>50 years oldNon-invasive + Invasive208Capsule-quellung testZhao et al. 2020147Beijing, Hebei, Shanxi, Liaoning, and ShandongApr. 2016 – Oct. 2017Pediatric and adult patients with IPDMost patients <5 years oldInvasive164Chessboard systemRen et al. 2021157Throughout China2011–2014Patients not identifiedPatients not identifiedInvasive102Capsule-quellung test + MPCRHuang et al. 2022167Seven Eastern Chinese hospitals2021Pediatric and Adult patientsMost patients <5 years oldNon-invasive + Invasive279MPCRZhou et al. 2022177various locations in China2010–2015Pediatric and Adult patientsaverage age: 46 ± 26.69 yearsInvasive299Capsule-quellung testAbbreviation: Sp, Streptococcal pneumoniae; PD, pneumococcal disease; IPD, invasive pneumococcal disease; NIPD, noninvasive pneumococcal disease; MPCR, multiple polymerase chain reaction. Characteristics of 159 included studies. Abbreviation: Sp, Streptococcal pneumoniae; PD, pneumococcal disease; IPD, invasive pneumococcal disease; NIPD, noninvasive pneumococcal disease; MPCR, multiple polymerase chain reaction. Pneumococcal isolates and serotype distribution A total of 36,477 Sp isolates from 159 studies were included in the final analysis. Among them, 11,361 (31.1%) were from North China, 16,445 (45.1%) from South China, and 8,671 (23.8%) were national. In terms of age, 24,422 (66.9%) isolates were from children (<18 years old), and 2,807 (7.7%) were from adults (≥18 years old), while the other 9,248 (25.4%) isolates did not specify age or were from all ages. A total of 4,491 (12.3%) isolates were invasive, 14,723 (40.4%) were noninvasive, and the other 17,263 (47.3%) were not stratified. Of the 36,477 included isolates, 1,671 were untyped and 2,535 were other strains (serogroup/serotype not presented). The top 10 serotypes in the count were 19F (9,771 strains, 26.79%), 19A (5,316 strains, 14.57%), 23F (3298 strains, 9.04%), 14 (2,558 strains, 7.01%), 6B (2,132 strains, 5.84%), 6A (2,030 strains, 5.57%), 3 (998 strains, 2.74%), 6 (631 strains, 1.73%), 15B (473 strains, 1.30%), and 9 V (466 strains, 1.28%). The differences in serotype distribution between strains source, isolated location, period, age group, and clinical manifestations are depicted in Figures 2 and 3. Figure 2.Proportion of top 10 serotypes among IPD and NIPD cases. Figure 3.a. Serotype distribution according to period. b. Serotype distribution according to age. c. Serotype distribution according to region. d. Serotype distribution according to manifestation. Proportion of top 10 serotypes among IPD and NIPD cases. a. Serotype distribution according to period. b. Serotype distribution according to age. c. Serotype distribution according to region. d. Serotype distribution according to manifestation. Meta-analysis of sp serotypes The results of the serotype meta-proportion can be found in Table 2. Of the 159 included studies, 19F was the most prevalent serotype causing PD (27.8%, 95%CI: 25.6–30.0%) (p < .001) in the Chinese Mainland, from January 1997 to July 2023. The serogroups/serotypes accounting for more than 10.0% were 19A (13.7%, 95%CI: 12.4–15.0%), and 6 (11.2%, 95%CI: 8.1–14.7%). These were followed by 23F (9.2%, 95%CI: 8.6–9.9%), 14 (8.8%, 95%CI: 7.9–9.7%), 6B (7.9%, 95%CI: 7.1–8.8%), 6A (6.6%, 95%CI: 5.2–8.3%), 3 (5.1%, 95%CI: 4.1–6.2%), 15B (2.5%, 95%CI: 2.0%–3.1%), and 9 V (2.5%, 95%CI: 1.9%–3.1%) (Table 2).Table 2.Top ten serotype distribution of streptococcus pneumoniae in total and each subgroup among the 159 included studies.StrainsSerotype/serogroupRelated studies, NPositive cases, NMeta- proportion95% CI of the meta- proportion*Test for heterogeneity,P valueTotalTotal included strains (n = 36,477) of all 159 studies19F156977127.8%25.6%–30.0%<0.00119A139531613.7%12.4%–15.0%<0.00161563111.2%8.1%–14.7%<0.00123F14732989.2%8.6%–9.9%<0.0011414325588.8%7.9%–9.7%<0.0016B11121327.9%7.1%–8.8%<0.0016A7920306.6%5.2%–8.3%<0.0013869985.1%4.1%–6.2%<0.00115B504732.5%2.0%–3.1%<0.0019 V714662.5%1.9%–3.1%<0.001LocationNorth ChinaStrains (n = 11,361) in 47 studies19F39226123.0%19.1%–27.1%<0.00119418826.1%17.2%–36.2%<0.00119A38188317.9%14.3%–21.8%<0.0016619912.2%9.1%–15.5%0.01223F3993810.0%8.3%–11.9%<0.00114418369.3%7.8%–10.9%<0.0016A269008.6%5.7%–12.0%<0.0016B294995.4%4.4%–6.4%<0.00115B121663.1%1.9%–4.6%<0.0019 V201413.0%1.9%–4.6%<0.001South ChinaStrains (n = 16,445) in 92 studies19F92498229.8%27.3%–32.95%<0.00119737920.5%0.86%–35.7%<0.00119A79188313.1%11.6%–14.6%<0.0016935111.0%0.67%–16.2%<0.00123F87157310.1%9.1%–11.1%<0.0016A/B142919.8%5.7%–14.7%<0.001148711759.0%7.7%–10.3%<0.0016B6811118.9%7.8%–10.1%<0.0016A425716.9%5.5%–8.5%<0.0013474684.9%3.4%–6.7%<0.001Sources of strainsInvasive strainsStrains (n = 4,491) in 53 studies19F5093222.0%19.6%–24.5%<0.00119A5082818.3%16.1%–20.6%<0.001145067116.1%14.2%–18.2%<0.00123F463908.3%7.2%–9.6%0.0096B332608.2%6.1%–10.7%<0.0013201535.2%3.6%–7.0%<0.0016A221124.0%2.4%–5.5%0.0219 V26843.6%2.6%–4.7%0.141515433.1%1.4%–5.2%<0.001114392.9%1.8%–4.2%<0.001Non-invasive strainsStrains (n = 14,723) in 65 studies19F57348929.9%25.6%–34.3%<0.00119A47198615.5%12.7%–18.4%<0.0016730312.5%10.8%–14.3%<0.00120622011.7%7.6%–16.6%<0.00123F54114910.1%8.9%–11.3%<0.0016A329699.0%6.5%–11.9%<0.00114578157.3%6.2%–8.4%<0.0016B466706.5%5.6%–7.5%<0.00115B212493.8%2.9%–4.8%<0.0013261913.8%2.3%–5.6%<0.001Patient ageChildren (<1 year old)Strains (n = 637) in 8 studies31947.4%27.3%–68.3%<0.00119F820125.4%17.9%–33.6%<0.00119A68816.1%12.7%–19.7%<0.0016A/B21211.0%5.3%–18.1%<0.00115A1910.6%5.7%–18.9%<0.0016A5489.5%6.3%–13.3%<0.00123F8569.2%5.0%–14.3%<0.0016B5318.0%2.8%–14.9%<0.001148547.5%5.4%–9.9%<0.0014155.9%2.5%–13.0%<0.001Children (2-3 years old)Strains (n = 17,97) in 13 studies19F1553929.6%25.6%–33.8%<0.001611418.7%11.5%–28.9%<0.00119A1425215.9%11.7%–20.7%<0.00123F1519710.3%8.7%–12.0%<0.0016B101467.9%4.5%–12.0%<0.00142137.4%3.6%–12.2%<0.00114151407.2%4.5%–10.4%<0.00136225.8%0.9%–13.8%0.0046A9835.6%3.9%–7.6%<0.0019 V5112.7%0.9%–5.2%<0.001Children (4-5 years old)Strains (n = 5,874in 36 studies19F37222831.2%26.0%–36.7%<0.00119634918.0%10.2%–27.4%<0.00119A3161512.1%9.8%–14.5%<0.0016A/B613012.0%4.2%–22.7%<0.00123F3759010.0%8.5%–11.5%<0.0012362189.5%4.6%–16.0%<0.0016B335479.0%7.3%–10.9%<0.001651828.8%4.2%–14.9%<0.00114384557.0%5.8%–8.4%<0.0016A212766.2%4.3%–8.3%<0.001Children (6–12 years old)Strains (n = 8,027) in 24 studies19F26129227.2%20.7%–34.2%<0.00119A20123620.8%16.1%–26.0%<0.001142141011.3%9.4%–13.4%<0.0016A1363410.5%5.5%–16.8%<0.00123F265219.1%7.8%–10.5%<0.0016B183367.3%5.6%–9.1%<0.0019 V131625.4%3.5%–7.6%<0.00186804.8%3.8%–5.9%<0.00115B91473.9%2.7%–5.4%<0.0016C4943.8%3.1%–4.6%<0.001Children (13–18 years old)Strains (n = 7,767) in 39 studies19F50251530.5%27.8%–33.2%<0.00119A45114816.4%14.2%–18.7%<0.0016718513.3%95%–17.5%<0.001144968010.9%8.9%–13.1%<0.00123F437049.3%8.1%–10.7%<0.0016A233187.8%6.2%–9.6%<0.0016B323977.0%5.7%–8.3%<0.00115B11993.2%2.3%–4.3%<0.0019 V20702.7%1.5%–4.2%<0.001318912.4%1.4%–3.7%<0.001AdultsStrains (n = 2,807) in 16 studies19222124.3%21.6%–27.2%<0.00119F1942821.6%17.4%–26.1%<0.00123113816.8%14.4%–19.5%<0.00119A1521712.2%10.8%–13.8%<0.00131730411.0%8.2%–14.1%<0.0016317210.1%1.9%–23.2%0.00223F191909.5%7.4%–11.9%<0.00114171857.1%5.7%–8.7%<0.0016B13764.6%2.8%–6.7%<0.0016A10543.5%2.2%–4.9%<0.001PeriodsBefore 2004Strains (n = 1,734) in 11 studies19F1022818.7%11.8%–26.8%<0.0016B45715.6%8.1%–24.8%0.00319212114.7%12.2%–17.4%<0.00123109611.6%9.4%–14.1%<0.001678310.0%7.9%–12.3%<0.00123F61099.6%7.2%–12.3%<0.0016A/B6828.7%1.2%–21.3%<0.00119A6728.7%4.3%–14.3%<0.0011441307.3%4.7%–10.3%<0.00134446.6%1.6%–14.4%<0.0012004–2008Strains (n = 3,349) in 17 studies19F16101834.0%25.3%–43.3%<0.001 19125223.6%20.8%–26.6%<0.001 6219920.1%17.6%–22.8%<0.001 23135116.8%14.4%–19.5%<0.001 19A1514314.2%10.9%–17.8%<0.001 23F162248.1%6.6%–9.6%0.066 14141877.7%5.2%–10.7%<0.001 381697.1%3.2%–12.3%<0.001 6B111195.9%4.6%–7.5%<0.001 153323.6%2.2%–5.3%0.6812009–2013Strains (n = 8,114) in 46 studies19F48257328.4%24.6%–32.3%<0.00119A45120713.6%11.6%–15.8%<0.0016310313.1%7.2%–20.5%<0.00123F449169.7%0.8%–11.5%0.00214457599.5%0.8%–11.2%<0.0016B365046.5%5.0%–8.1%<0.0013293655.7%4.1%–7.6%<0.0016A253155.5%4.2%–7.1%<0.0019 V251132.1%1.3%–3.1%0.02315A13711.6%0.9%–2.4%0.012014–2018Strains (n = 21,376) in 73 studies19F80627027.9%25.0%–30.9%<0.00119A72383914.7%12.9%–16.5%<0.0016A/B1126010.4%6.3%–15.2%<0.00123F7421539.4%8.6%–10.2%<0.001147215449.1%7.9%–10.5%<0.0016B6014728.5%7.4%–9.7%<0.0016A4516986.6%4.6%–8.9%<0.0013404384.4%3.2%–5.8%<0.00115B263942.8%2.0%–3.7%<0.0019 V382991.7%1.7%–3.5%<0.0012019–2023Strains (n = 1,274 in 9 studies)19F930724.8%20.2%–29.7%0.0046A67614.5%4.9%–27.6%<0.00119A715811.8%5.7%–19.5%<0.0016A/B25911.4%8.5%–14.7%<0.00123F81078.0%6.0%–10.3%0.157147956.8%2.1%–13.3%<0.0016B6636.3%2.6%–11.3%<0.00115A5445.3%3.4%–7.5%<0.00134203.3%1.2%–6.2%0.0619 V6442.3%0.2%–6.0%<0.001ManifestationsRespiratory infectionsStrains (n = 14,327) in 58 studies19F52332929.5%24.5%–34.8%<0.00119854616.3%10.1%–23.7%<0.00161050112.5%9.0%–16.4%<0.00119A39154011.5%8.7%–14.5%<0.00123F50117510.7%9.3%–12.2%<0.00123735610.6%6.2%–15.9%<0.0016A3110159.5%6.8%–12.6%<0.0016B386588.4%6.8%–10.2%<0.00114507096.7%5.7%–7.8%<0.0013222724.7%2.3%–7.8%<0.001Respiratory infectionsUpper respiratory infectionsStrains (n = 2,806) in 9 studies19429723.6%17.3%–30.4%<0.00123420714.9%10.9%–19.3%<0.0016418212.7%10.3%–15.3%<0.00119F46012.0%7.3%–17.6%0.02919A196.7%3.5%–12.2%<0.00123F45210.2%7.7%–13.1%0.6376A512810.0%7.2%–13.2%0.003815B167.7%3.6%–15.8%<0.0016B4696.8%5.7%–7.9%<0.001155724.5%3.5%–5.7%<0.001Respiratory infectionsLower respiratory infectionsStrains (n = 6,215) in 26 studies19F26204435.3%29.1%–41.8%<0.001 19219419.1%16.6%–21.7%<0.001 23213813.5%11.4%–15.8%<0.001 6631912.3%6.5%–19.4%<0.001 23F2561411.4%9.7%–13.3%<0.001 19A225319.2%7.3%–11.2%<0.001 6B183218.1%6.4%–10.0%<0.001 6A112117.1%4.3%–10.5%<0.001 14202925.6%4.2%–7.2%<0.001 3132134.4%1.6%–8.4%<0.001Acute otitis media (AOM)Strains (n = 373) in 4 studies19F413149.5%32.7%–66.4%<0.0016A1628.6%13.8%–50.0%<0.001 19A34015.0%2.4%–34.7%0.0036B3217.3%1.0%–17.9%0.00523F2135.4%2.6%–9.0%<0.0013274.6%1.5%–8.9%<0.00115112.7%0.5%–13.8%0.156142123.2%0.7%–6.9%0.00119A/19F121.9%0.5%–6.5%0.031MeningitisStrains (N = 130) in 4 studies1442821.2%14.3%–29.0%<0.00119F42721.1%12.0%–31.6%<0.0016B21818.8%11.4%–27.5%<0.00119A41712.5%7.0%–19.2%<0.00123F41712.4%6.9%–19.0%<0.0016A2410.8%1.9%–24.1%0.0039 V137.7%2.7%–20.3%0.00615B/C125.1%1.4%–16.9%0.03115B114.2%0.7%–20.2%0.15620112.5%0.5%–13.2%0.156Eye infectionStrains (n = 81) in 2 studies1911210.2%0–52.0%<0.001142810.8%5.1%–18.3%0.9098279.6%4.2%–16.8%0.78919F287.5%0–38.7%<0.00115246.0%1.9%–12.0%0.93420246.0%1.9%–12.0%0.93411223.5%0.7%–8.5%0.95012223.5%0.7%–8.5%0.95017223.5%0.7%–8.5%0.9506B122.6%0.3%–7.0%0.111Abbreviation: CI, confidence interval; N.number.*The Q test of Heterogeneity. A p value of < 0.05 was considered statistically significant. Table 2.Top ten serotype distribution of streptococcus pneumoniae in total and each subgroup among the 159 included studies.StrainsSerotype/serogroupRelated studies, NPositive cases, NMeta- proportion95% CI of the meta- proportion*Test for heterogeneity,P valueTotalTotal included strains (n = 36,477) of all 159 studies19F156977127.8%25.6%–30.0%<0.00119A139531613.7%12.4%–15.0%<0.00161563111.2%8.1%–14.7%<0.00123F14732989.2%8.6%–9.9%<0.0011414325588.8%7.9%–9.7%<0.0016B11121327.9%7.1%–8.8%<0.0016A7920306.6%5.2%–8.3%<0.0013869985.1%4.1%–6.2%<0.00115B504732.5%2.0%–3.1%<0.0019 V714662.5%1.9%–3.1%<0.001LocationNorth ChinaStrains (n = 11,361) in 47 studies19F39226123.0%19.1%–27.1%<0.00119418826.1%17.2%–36.2%<0.00119A38188317.9%14.3%–21.8%<0.0016619912.2%9.1%–15.5%0.01223F3993810.0%8.3%–11.9%<0.00114418369.3%7.8%–10.9%<0.0016A269008.6%5.7%–12.0%<0.0016B294995.4%4.4%–6.4%<0.00115B121663.1%1.9%–4.6%<0.0019 V201413.0%1.9%–4.6%<0.001South ChinaStrains (n = 16,445) in 92 studies19F92498229.8%27.3%–32.95%<0.00119737920.5%0.86%–35.7%<0.00119A79188313.1%11.6%–14.6%<0.0016935111.0%0.67%–16.2%<0.00123F87157310.1%9.1%–11.1%<0.0016A/B142919.8%5.7%–14.7%<0.001148711759.0%7.7%–10.3%<0.0016B6811118.9%7.8%–10.1%<0.0016A425716.9%5.5%–8.5%<0.0013474684.9%3.4%–6.7%<0.001Sources of strainsInvasive strainsStrains (n = 4,491) in 53 studies19F5093222.0%19.6%–24.5%<0.00119A5082818.3%16.1%–20.6%<0.001145067116.1%14.2%–18.2%<0.00123F463908.3%7.2%–9.6%0.0096B332608.2%6.1%–10.7%<0.0013201535.2%3.6%–7.0%<0.0016A221124.0%2.4%–5.5%0.0219 V26843.6%2.6%–4.7%0.141515433.1%1.4%–5.2%<0.001114392.9%1.8%–4.2%<0.001Non-invasive strainsStrains (n = 14,723) in 65 studies19F57348929.9%25.6%–34.3%<0.00119A47198615.5%12.7%–18.4%<0.0016730312.5%10.8%–14.3%<0.00120622011.7%7.6%–16.6%<0.00123F54114910.1%8.9%–11.3%<0.0016A329699.0%6.5%–11.9%<0.00114578157.3%6.2%–8.4%<0.0016B466706.5%5.6%–7.5%<0.00115B212493.8%2.9%–4.8%<0.0013261913.8%2.3%–5.6%<0.001Patient ageChildren (<1 year old)Strains (n = 637) in 8 studies31947.4%27.3%–68.3%<0.00119F820125.4%17.9%–33.6%<0.00119A68816.1%12.7%–19.7%<0.0016A/B21211.0%5.3%–18.1%<0.00115A1910.6%5.7%–18.9%<0.0016A5489.5%6.3%–13.3%<0.00123F8569.2%5.0%–14.3%<0.0016B5318.0%2.8%–14.9%<0.001148547.5%5.4%–9.9%<0.0014155.9%2.5%–13.0%<0.001Children (2-3 years old)Strains (n = 17,97) in 13 studies19F1553929.6%25.6%–33.8%<0.001611418.7%11.5%–28.9%<0.00119A1425215.9%11.7%–20.7%<0.00123F1519710.3%8.7%–12.0%<0.0016B101467.9%4.5%–12.0%<0.00142137.4%3.6%–12.2%<0.00114151407.2%4.5%–10.4%<0.00136225.8%0.9%–13.8%0.0046A9835.6%3.9%–7.6%<0.0019 V5112.7%0.9%–5.2%<0.001Children (4-5 years old)Strains (n = 5,874in 36 studies19F37222831.2%26.0%–36.7%<0.00119634918.0%10.2%–27.4%<0.00119A3161512.1%9.8%–14.5%<0.0016A/B613012.0%4.2%–22.7%<0.00123F3759010.0%8.5%–11.5%<0.0012362189.5%4.6%–16.0%<0.0016B335479.0%7.3%–10.9%<0.001651828.8%4.2%–14.9%<0.00114384557.0%5.8%–8.4%<0.0016A212766.2%4.3%–8.3%<0.001Children (6–12 years old)Strains (n = 8,027) in 24 studies19F26129227.2%20.7%–34.2%<0.00119A20123620.8%16.1%–26.0%<0.001142141011.3%9.4%–13.4%<0.0016A1363410.5%5.5%–16.8%<0.00123F265219.1%7.8%–10.5%<0.0016B183367.3%5.6%–9.1%<0.0019 V131625.4%3.5%–7.6%<0.00186804.8%3.8%–5.9%<0.00115B91473.9%2.7%–5.4%<0.0016C4943.8%3.1%–4.6%<0.001Children (13–18 years old)Strains (n = 7,767) in 39 studies19F50251530.5%27.8%–33.2%<0.00119A45114816.4%14.2%–18.7%<0.0016718513.3%95%–17.5%<0.001144968010.9%8.9%–13.1%<0.00123F437049.3%8.1%–10.7%<0.0016A233187.8%6.2%–9.6%<0.0016B323977.0%5.7%–8.3%<0.00115B11993.2%2.3%–4.3%<0.0019 V20702.7%1.5%–4.2%<0.001318912.4%1.4%–3.7%<0.001AdultsStrains (n = 2,807) in 16 studies19222124.3%21.6%–27.2%<0.00119F1942821.6%17.4%–26.1%<0.00123113816.8%14.4%–19.5%<0.00119A1521712.2%10.8%–13.8%<0.00131730411.0%8.2%–14.1%<0.0016317210.1%1.9%–23.2%0.00223F191909.5%7.4%–11.9%<0.00114171857.1%5.7%–8.7%<0.0016B13764.6%2.8%–6.7%<0.0016A10543.5%2.2%–4.9%<0.001PeriodsBefore 2004Strains (n = 1,734) in 11 studies19F1022818.7%11.8%–26.8%<0.0016B45715.6%8.1%–24.8%0.00319212114.7%12.2%–17.4%<0.00123109611.6%9.4%–14.1%<0.001678310.0%7.9%–12.3%<0.00123F61099.6%7.2%–12.3%<0.0016A/B6828.7%1.2%–21.3%<0.00119A6728.7%4.3%–14.3%<0.0011441307.3%4.7%–10.3%<0.00134446.6%1.6%–14.4%<0.0012004–2008Strains (n = 3,349) in 17 studies19F16101834.0%25.3%–43.3%<0.001 19125223.6%20.8%–26.6%<0.001 6219920.1%17.6%–22.8%<0.001 23135116.8%14.4%–19.5%<0.001 19A1514314.2%10.9%–17.8%<0.001 23F162248.1%6.6%–9.6%0.066 14141877.7%5.2%–10.7%<0.001 381697.1%3.2%–12.3%<0.001 6B111195.9%4.6%–7.5%<0.001 153323.6%2.2%–5.3%0.6812009–2013Strains (n = 8,114) in 46 studies19F48257328.4%24.6%–32.3%<0.00119A45120713.6%11.6%–15.8%<0.0016310313.1%7.2%–20.5%<0.00123F449169.7%0.8%–11.5%0.00214457599.5%0.8%–11.2%<0.0016B365046.5%5.0%–8.1%<0.0013293655.7%4.1%–7.6%<0.0016A253155.5%4.2%–7.1%<0.0019 V251132.1%1.3%–3.1%0.02315A13711.6%0.9%–2.4%0.012014–2018Strains (n = 21,376) in 73 studies19F80627027.9%25.0%–30.9%<0.00119A72383914.7%12.9%–16.5%<0.0016A/B1126010.4%6.3%–15.2%<0.00123F7421539.4%8.6%–10.2%<0.001147215449.1%7.9%–10.5%<0.0016B6014728.5%7.4%–9.7%<0.0016A4516986.6%4.6%–8.9%<0.0013404384.4%3.2%–5.8%<0.00115B263942.8%2.0%–3.7%<0.0019 V382991.7%1.7%–3.5%<0.0012019–2023Strains (n = 1,274 in 9 studies)19F930724.8%20.2%–29.7%0.0046A67614.5%4.9%–27.6%<0.00119A715811.8%5.7%–19.5%<0.0016A/B25911.4%8.5%–14.7%<0.00123F81078.0%6.0%–10.3%0.157147956.8%2.1%–13.3%<0.0016B6636.3%2.6%–11.3%<0.00115A5445.3%3.4%–7.5%<0.00134203.3%1.2%–6.2%0.0619 V6442.3%0.2%–6.0%<0.001ManifestationsRespiratory infectionsStrains (n = 14,327) in 58 studies19F52332929.5%24.5%–34.8%<0.00119854616.3%10.1%–23.7%<0.00161050112.5%9.0%–16.4%<0.00119A39154011.5%8.7%–14.5%<0.00123F50117510.7%9.3%–12.2%<0.00123735610.6%6.2%–15.9%<0.0016A3110159.5%6.8%–12.6%<0.0016B386588.4%6.8%–10.2%<0.00114507096.7%5.7%–7.8%<0.0013222724.7%2.3%–7.8%<0.001Respiratory infectionsUpper respiratory infectionsStrains (n = 2,806) in 9 studies19429723.6%17.3%–30.4%<0.00123420714.9%10.9%–19.3%<0.0016418212.7%10.3%–15.3%<0.00119F46012.0%7.3%–17.6%0.02919A196.7%3.5%–12.2%<0.00123F45210.2%7.7%–13.1%0.6376A512810.0%7.2%–13.2%0.003815B167.7%3.6%–15.8%<0.0016B4696.8%5.7%–7.9%<0.001155724.5%3.5%–5.7%<0.001Respiratory infectionsLower respiratory infectionsStrains (n = 6,215) in 26 studies19F26204435.3%29.1%–41.8%<0.001 19219419.1%16.6%–21.7%<0.001 23213813.5%11.4%–15.8%<0.001 6631912.3%6.5%–19.4%<0.001 23F2561411.4%9.7%–13.3%<0.001 19A225319.2%7.3%–11.2%<0.001 6B183218.1%6.4%–10.0%<0.001 6A112117.1%4.3%–10.5%<0.001 14202925.6%4.2%–7.2%<0.001 3132134.4%1.6%–8.4%<0.001Acute otitis media (AOM)Strains (n = 373) in 4 studies19F413149.5%32.7%–66.4%<0.0016A1628.6%13.8%–50.0%<0.001 19A34015.0%2.4%–34.7%0.0036B3217.3%1.0%–17.9%0.00523F2135.4%2.6%–9.0%<0.0013274.6%1.5%–8.9%<0.00115112.7%0.5%–13.8%0.156142123.2%0.7%–6.9%0.00119A/19F121.9%0.5%–6.5%0.031MeningitisStrains (N = 130) in 4 studies1442821.2%14.3%–29.0%<0.00119F42721.1%12.0%–31.6%<0.0016B21818.8%11.4%–27.5%<0.00119A41712.5%7.0%–19.2%<0.00123F41712.4%6.9%–19.0%<0.0016A2410.8%1.9%–24.1%0.0039 V137.7%2.7%–20.3%0.00615B/C125.1%1.4%–16.9%0.03115B114.2%0.7%–20.2%0.15620112.5%0.5%–13.2%0.156Eye infectionStrains (n = 81) in 2 studies1911210.2%0–52.0%<0.001142810.8%5.1%–18.3%0.9098279.6%4.2%–16.8%0.78919F287.5%0–38.7%<0.00115246.0%1.9%–12.0%0.93420246.0%1.9%–12.0%0.93411223.5%0.7%–8.5%0.95012223.5%0.7%–8.5%0.95017223.5%0.7%–8.5%0.9506B122.6%0.3%–7.0%0.111Abbreviation: CI, confidence interval; N.number.*The Q test of Heterogeneity. A p value of < 0.05 was considered statistically significant. Top ten serotype distribution of streptococcus pneumoniae in total and each subgroup among the 159 included studies. Abbreviation: CI, confidence interval; N. number. *The Q test of Heterogeneity. A p value of < 0.05 was considered statistically significant. Proportion of PD serotypes in IPD and NIPD As shown in Table 2, the 10 most prevalent serotypes in IPD were 19F (22.0%, 95%CI: 19.6–24.5%), 19A (18.3%, 95%CI: 16.1–20.6%), 14 (16.1%, 95%CI: 14.2–18.2%), 23F (8.3%, 95%CI: 7.2–9.6%), 6B (8.2%, 95%CI: 6.1–10.7%), 3 (5.2%, 95%CI: 3.6–7.0%), 6A (4.0%, 95%CI: 2.4–5.5%), 9 V (3.6%, 95%CI: 2.6–4.7%), 5 (3.1%, 95%CI: 1.4–5.2%), and 1 (2.9%, 95%CI: 1.8–4.2%). The statistically predominating serotype in the NIPD was 19F with almost one-third distribution (29.9%, 95%CI: 25.6–34.3%). The following predominant serotypes were 19A (15.5%, 95%CI: 12.7–18.4%), 6 (12.5%, 95%CI: 10.8–14.3%), 20 (11.7%, 95%CI: 7.6–16.6%), 23F (10.1%, 95%CI: 8.9–11.3%), 6A (9.0%, 95%CI: 6.5–11.9%), 14 (7.3%, 95%CI: 6.2–8.4%), 6B (6.5%, 95%CI: 5.6–7.5%), 15B (3.8%, 95%CI: 2.9–4.8%), and 3 (3.8%, 95%CI: 2.3–5.6%). Proportion of PD serotypes in different clinical manifestations There were 58 studies with 14.327 strains isolated from patients with respiratory infections (Table 2). The top five most common serotypes were 19F (29.5%, 95%CI: 24.5–34.8%), 19 (16.3%, 95%CI: 10.1–23.7%), 6 (12.5%, 95%CI: 9.0–16.4%), 19A (11.5%, 95%CI: 8.7–14.5%), and 23F (10.7%, 95%CI: 9.3–12.2%). Although the sequence of the distribution was different between lower and upper respiratory infections, the serogroups 19 (including 19F and 19A), 23 (including 23F), and 6 (including 6A and 6B), were prominently high in both manifestations. Four studies reported 373 strains isolated from acute otitis media (AOM). The key serotypes were 19F (49.5%, 95%CI: 32.7–66.4%) and 6A (28.6%, 95%CI: 13.8–50.0%), which accounted for more than 78% of the serotype distribution. Four studies reported strains (n = 130) from meningitis. The top five most prevalent serogroups/serotypes were 14 (21.2%, 95%CI: 14.3–29.0%), 19F (21.1%, 95%CI: 12.0–31.6%), 6B (18.8%, 95%CI: 11.4–27.5%), 19A (12.5%, 95%CI: 7.0–19.2%), and 23F (12.4%, 95%CI: 6.9–19.0%). Serotype 14, serogroup 6B, and serotype 9 V (7.7%, 95%CI: 2.7–20.3%) were higher in meningitis than in other clinical manifestations. Two studies reported 81 strains isolated from eye infections, in which there were high proportions of serotypes 19 and 14. Proportion of PD serotypes in south and North China There were 16,445 strains (92 studies) and 11,361 strains (53 studies) from South and North China, respectively. Serotypes 9 V and 15B were only present in the top 10 serotypes in the North, while serotypes 3 and 6A/B were only present in the top 10 serotypes in the South. The meta-proportion of 19F and 6B were significantly higher in North China than those in South China (Supplementary Figure S1). Proportion of PD serotypes in different age groups There were more studies (106 studies 24,422 isolates) that reported on children with PD compared to adults with PD (16 studies, 2,807 isolates). As shown in Table 3, there does not appear to be a noticeable difference in the TOP10 serotype categories between age groups. However, the proportion of serotype 3 differed significantly between age groups. The proportion of serotype 3 was higher in children under 1 year (47.4%, 95%CI: 27.3–68.3%) and adults (11.0%, 95%CI: 8.2–14.1%) than other age groups, especially for those <1 year. There were no significant differences in the proportions of serotypes 19F, 19A, 23F, and 14 among the different children age groups (<1 year, 2–3 years, 4–5 years, 6–12 years, and 13–18 years) (Supplementary Figure S2).Table 3.Sensitivity analysis.Sensitivity analysisTotal included strains (n = 34675) of 155 studies19F155969227.7%25.5%–30.0%<0.00119A139531613.7%12.4%–15.0%<0.00161236910.2%6.4%–14.6%<0.00123F14632899.3%8.6%–10.0%<0.0011413924588.9%8.0%–9.9%<0.0016B11121327.9%7.1%–8.8%<0.0016A7920306.6%5.2%–8.3%<0.0013838504.9%4.0%–6.0%<0.00115B504732.5%2.0%–3.1%<0.0019 V714662.5%1.9%–3.1%<0.001Abbreviation: CI, confidence interval; N.number*The Q test of Heterogeneity. A P-value of < 0.05 was considered statistically significant. Table 3.Sensitivity analysis.Sensitivity analysisTotal included strains (n = 34675) of 155 studies19F155969227.7%25.5%–30.0%<0.00119A139531613.7%12.4%–15.0%<0.00161236910.2%6.4%–14.6%<0.00123F14632899.3%8.6%–10.0%<0.0011413924588.9%8.0%–9.9%<0.0016B11121327.9%7.1%–8.8%<0.0016A7920306.6%5.2%–8.3%<0.0013838504.9%4.0%–6.0%<0.00115B504732.5%2.0%–3.1%<0.0019 V714662.5%1.9%–3.1%<0.001Abbreviation: CI, confidence interval; N.number*The Q test of Heterogeneity. A P-value of < 0.05 was considered statistically significant. Sensitivity analysis. Abbreviation: CI, confidence interval; N. number *The Q test of Heterogeneity. A P-value of < 0.05 was considered statistically significant. Proportion of PD serotypes in different study periods According to the study period, we categorized the included studies into five groups: before 2004 (11 studies), 2004–2008 (17 studies), 2009–2013 (46 studies), 2014–2018 (73 studies), and 2019–2023 (9 studies). A sufficiently large sample size was obtained for each of the periods. Before 2004, there was a higher ratio of serogroups versus serotypes due to limitations in pneumococcal-serotyping methods. In the recent decade, there have been no reports of serogroups 19 and 23, but there have been further divisions to exact serotypes. The distribution of the top 10 serotypes according to period can be found in Table 2. Serogroup 19 and serotypes 19F and 19A have kept showing a predominantly prevalent serogroup/serotype. Serotype 6A only showed up after 2009 and have been progressively more prevalent in recent years. It became the TOP2 prevalent serotypes in 2019–2023. In 2019–2023, the top 10 serotypes with the highest proportion were serogroups 19F, 6A, 19A, 6A/B, 23F, 14, 6B, 15A, 3, and 9 V. Notably, serotype 15A was non-PCV13 and non-PSV23 vaccine serotypes. The proportion of 15A was TOP8 (5.3%, 95%CI: 3.4–7.5%) in 2019–2023. Comparing to the previous periods, the serotype 15A has the tendency of increasing. Sensitivity analysis Sensitivity analysis was conducted to determine study quality assessment. After deleting five studies with a high risk of deviation in the study quality assessment,28,45,80,118 According to the sensitivity analysis, the meta-proportion of the top 10 serotypes can be found in Table 3. Although the proportions of the top 10 serotypes changed slightly, the ordering of these serotypes did not change. The sensitivity results were consistent with the initial findings, which confirmed the robustness of the findings of our study. Discussion In this study, we systematically reviewed the prevalence of Sp serotypes causing PD in the Chinese Mainland from January 1997 to July 2023. This meta-analysis indicated that the highest overall proportion in PD was 19F with 27.8% in our study period. This finding was followed by 19A, 6, 23F, 14, 6B, 6A, 3, 15B, and 9 V. 19F was the predominant Sp serotype in PD patients, which was consistent with the results of a meta-analysis based on the Chinese Mainland in 2018.15 When comparing the top 10 most common serotypes, a 2018 review also identified 19F, 19A, 14, 6B, and 6A among the top 10 most common serotypes, confirming our findings. We found the top 10 serotypes with the highest proportion were serogroups 19F, 6A, 19A, 6A/B, 23F, 14, 6B, 15A, 3, and 9 V in recent publications (2019–2023). Among those serotypes, serotype 6A increased to the TOP2 prevalent serotype, and 15A belongs to NVTs. This finding was similar to the increased proportion of PD caused by NVTs in other geographical areas in recent years.180 As previously studied, the serotype distribution of PD slightly varies across location.181,182 A report for PD patients in South East Asia identified the most common causative serotypes as 19F, 23F, 14, 6B, 1, 19A, and 3.183 Recently published reviews found that the most common disease-causing serotypes were 6B, 23F, 14, 19A, and 19F in Thailand,181 and 19F, 23F, 14, 6B, and 19A in Malaysia.184 Serotype distribution variation has also been investigated in Europe and other regions.182,185 The prevalent serotypes of PD also varied between North and South China. In this study, serotypes 19 serogroup, including 19F and 19A, were the most prevalent serotypes of PD in North and South China. Besides, although proportion of strains varied between the two regions of China, most of the composition of top strains was similar in the south and the north. However, according to our meta-analysis, the meta-proportion of 19F and 6B were significantly higher in North China than those in South China. Thus, PD prevention and control require regional consideration. The distribution of Sp serotypes in China varies depending on time and period of vaccination. According to our analysis, the proportion of 15A, non-PCV13 and non-PSV23 vaccine serotype, was TOP8 in 2019–2023. Comparing to the previous periods, the serotype 15A has the tendency of increasing. After the introduction of PCV, an increase in NVTs has been reported in IPD for both children and adults. It was reported that, after the introduction of PCV7, serotypes were replaced by non-vaccine serotypes, including 15A.186 Lochen et al. stated that NVT serotypes (e.g., 8, 9N, 15A and 23B) are increasing in the several countries.187 In France, as a NVT, serotype 15A was rarely isolated from pneumonia cases, but particularly involved in IPD in patients with underlying conditions after the implementation of PCV13.188 In Japan, after routinely vaccinating PCV, 15A became the third most prevalent serotype in pediatric IPD patients, and serotypes 15A were highly non-susceptible to penicillin.189 Another Japan study also identified 15A as one of the emerging NVT serotypes after PCV7.190 Vaccination is regarded as the optimal strategy to prevent PD. In the Chinese Mainland, PCV7 and PCV13 were licensed in 2008 and 2016, respectively. Although the general vaccination rate is low, it has been gradually increasing in recent years. The estimated 2017 national three-dose coverage in the private market was 1.3% for PCV among children aged 1 − 59 months,14 but this coverage increased to 16.13% in 2021, and 35.44% of infants received at least one dose of the PCV.191 Increased vaccination coverage is a possible cause of the higher proportion of non-vaccine serotypes. The increased proportion of NVTs is also likely to be related to the upgrading of Sp serotyping methods, with previously untyped NVTs being detected.192–194 With the development and widespread availability of molecular biology serotyping methods and sequencing technologies, methods enabling the detection or prediction of a broader variety of serotypes than the quellung reaction or traditional PCR have been used. Stronger investment in respiratory infectious disease surveillance in recent years would also increase the serotyping rate of Sp isolates, especially those previously classified as others. Also, modifications of the organisms may contribute to such variations. Our results indicate that the increasing proportion of NVTs is a concern that we need to face in PD prevention and control, despite currently low levels of vaccination. Various potential factors, including vaccination, lead to variations in the serotype profile of PD and need further research. The serotype prevalence and the diversity of serotype replacements following PCV vaccine application in different countries and regions also requires ongoing monitoring. There is variation among pneumococcal serotypes in their potential to cause PD and clinical manifestations. From invasive and noninvasive strains, serotypes 9 V, 5, and 1 were included in the TOP10 serotypes causing IPD but not NIPD. There was no significant difference between the remaining high proportion of serotypes of invasive and noninvasive strains. However, the proportion of each serotype was different. Serotypes with proportions over 10% in IPD consisted of 19F, 19A, and 14, with the highest proportion being 22.0% for serotype 19F. Similarly, 19F and 19A accounted for the majority of NIPD, up to 29.9% and 15.5%, respectively. Our results are consistent with the previous studies, in which the most common cause of IPD and NIPD in the Chinese Mainland was 19F, followed by 19A.15,16 Serotype 14 was the most prevalent serotypes in European childhood IPD from 1990 to 2008,195 and 19A was the most predominant serotype in IPD worldwide.180,196 From clinical manifestations, the common Sp serotypes (proportion >5%) corresponding to different manifestations can be diverse. According to our analysis, for upper respiratory infection, the most common serogroups/serotypes were 19, 23, and 6; for lower respiratory infection they were 19F, 19, and 23; for AOM they were 19F, 6A, and 19A; for meningitis they were 14, 19F, and 6B; for eye infection they were 19, 14, and 8. The serotype distribution of Sp according to the clinical manifestations was reported to be diverse in different regions worldwide.197–201 As the susceptibility of different Sp serotypes to antibiotics can be quite different.189,201 Understanding the distribution of Sp serotypes is crucial for PD prevention and clinical treatment in China, especially with regard to vaccine strategy and antimicrobial agent selection. Serogroup 3 is considered highly invasive and is associated with a high risk of mortality.202 Although serotype 3 is a vaccine serotype, the introduction of pneumococcal vaccine failed to control IPD caused by serotype 3.203–205 Serotype 3 also appears to be more likely to cause IPD in adults, especially in adult older than 65 years. The proportion of serotype 3 has been reported to be significantly higher in adults than in children.182 Importantly, our study showed a high prevalence of serotype 3 in PD cases not only in adults but also in children less than 1 year in the Chinese Mainland. Clarifying the serotype prevalence of PD cases at different age groups and clarification of the underlying mechanism related to age-associated Sp serotype differences are significant for the development of Sp vaccines and the formulation of Sp vaccination strategies. It is challenging to explore the general Sp serotype distribution only using a local and/or small-scale survey, especially for China, which is a large and highly populated country with geographically diverse climates. A systematic review of the prevalence of Sp serotypes causing PD in the Chinese Mainland is helpful for PD prevention and control, vaccine development, and vaccination. However, there are a few limitations of this study. First, the overall quality of the literature was challenging, as it was mostly comprised of retrospective and/or observational studies. Second, some studies, especially those in earlier years, may not have reported the exact serotype and only provided the serogroup due to lack of serotyping methods or insufficient serotyping capabilities, which makes comparative analysis of subgroups difficult. Lastly, the heterogeneity detected in the present analysis cannot be ignored. Although sensitivity analysis was used to ensure the validity of the results, these limitations must be considered when interpreting the findings of this meta-analysis. In the future, timely updating of serotype distribution of Sp is necessary. Conclusions This systematic review showed that, from 1997 to 2023 in the Chinese Mainland, the top 10 Sp serotypes in PD patients were 19F, 19A, 6, 23F, 14, 6B, 6A, 3, 15B, and 9 V. Although the distribution of serotypes varies according to strain source, location, age, manifestation, and period, the increase in non-vaccine serotypes such as 15A in recent years should not be ignored. The current serotype distribution in the Chinese Mainland highlights the long-term sustained exploration of localized serotype prevalence as being essential for PD vaccine policies, prevention, and treatment. Policy makers should be vigilant in monitoring the serotype distribution of Sp in their attempts to reduce the burden of PD in China. Supplementary Material Supplementary Figure 1.tif Supplementary Figure 2.tif